WO2004103463A1 - Implantable medical device with a nonhermetic battery - Google Patents

Implantable medical device with a nonhermetic battery Download PDF

Info

Publication number
WO2004103463A1
WO2004103463A1 PCT/US2004/014804 US2004014804W WO2004103463A1 WO 2004103463 A1 WO2004103463 A1 WO 2004103463A1 US 2004014804 W US2004014804 W US 2004014804W WO 2004103463 A1 WO2004103463 A1 WO 2004103463A1
Authority
WO
WIPO (PCT)
Prior art keywords
components
imd
nonhermetic battery
power source
interconnect member
Prior art date
Application number
PCT/US2004/014804
Other languages
French (fr)
Other versions
WO2004103463B1 (en
Inventor
Erik R. Scott
Carl D. Wahlstrand
Robert M. Skime
Craig L. Schmidt
Original Assignee
Medtronic, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medtronic, Inc. filed Critical Medtronic, Inc.
Priority to DE602004029351T priority Critical patent/DE602004029351D1/en
Priority to AT04751949T priority patent/ATE482741T1/en
Priority to EP04751949A priority patent/EP1624923B1/en
Publication of WO2004103463A1 publication Critical patent/WO2004103463A1/en
Publication of WO2004103463B1 publication Critical patent/WO2004103463B1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/18Applying electric currents by contact electrodes
    • A61N1/32Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/372Arrangements in connection with the implantation of stimulators
    • A61N1/375Constructional arrangements, e.g. casings
    • A61N1/37514Brain implants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/18Applying electric currents by contact electrodes
    • A61N1/32Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/372Arrangements in connection with the implantation of stimulators
    • A61N1/378Electrical supply

Definitions

  • the invention relates to medical devices, and more particularly, to implantable medical devices.
  • implantable medical devices may include a variety of electrical and/or mechanical components.
  • an IMD includes a rigid housing that houses all of its components, which are generally fragile, to protect the components from forces to which they would otherwise be exposed when implanted within the human body.
  • IMD housings are typically hermetically sealed.
  • Many IMD housings are fabricated from titanium because of its desirable rigidity and biocompatibility.
  • the size and shape of an IMD housing is dependent on the sizes and shapes of the components of the IMD.
  • Large components common to most IMDs include a battery and a circuit board that carries digital circuits, e.g., integrated circuit chips and/or a microprocessor, and analog circuit components. Attempts have been made to reduce the size of the IMD housing by reducing the size of these components, changing the shape of these components, and organizing these components within the IMD housing to avoid empty space within the housing.
  • the functional and safety requirements of IMDs have limited attempts to reduce the size and improve the shape of rigid IMD housings.
  • hermetic batteries e.g., batteries within a hermetically sealed housing or case
  • the need to make the housing or case of the battery hermetic limits the thinness and shapes that the battery may have, e.g., due to need for hermetic feedthroughs and the type of welding required for a hermetic housing or case.
  • IMD housings still greatly limit the locations within the human body where an IMD can be practically implanted. Due to these limitations, an IMD is typically implanted within the abdomen, upper pectoral region, or subclavicular region of a patient. Leads or catheters must be used in order to deliver therapy or monitor a physiological parameter at a location of the body other than where the IMD is implanted. Implantation and positioning of leads and catheters can be difficult and time- consuming from the perspective of a surgeon, particularly where the IMD is located a significant distance from the treatment or monitoring site.
  • IMDs that are used to treat or monitor the brain e.g., to deliver deep brain stimulation (DBS) therapy
  • DBS deep brain stimulation
  • IMDs that are used to treat or monitor the brain are implanted some distance away from the brain, e.g., within the subclavicular region of patients.
  • the long leads that connect the implantable medical device to electrodes implanted within the brain require tunneling under the scalp and the skin of the neck, thereby requiring extensive surgery and a prolonged amount of time under general anesthesia during the implant procedure, as well as increased recovery time.
  • tunneling the leads under the scalp and skin of the neck requires an additional surgical procedure under general anesthesia.
  • the lengthy tract along the leads is more susceptible to infection, and the leads can erode the overlying scalp, forcing removal so that the scalp can heal.
  • the long leads running under the scalp and through the neck are more susceptible to fracture due to torsional and other forces caused by normal head and neck movements.
  • the invention is directed to an implantable medical device (IMD) including a nonhermetic battery, i.e., a battery that is contained within a nonhermetic housing or other nonhermetic enclosure.
  • the IMD includes components and a power source module that includes the nonhermetic battery.
  • the nonhermetic battery delivers power to the components via an electrical conductor that extends from the nonhermetic battery to the components.
  • the IMD may comprise a modular IMD.
  • the IMD includes a control module that includes the components within a control module housing and an interconnect member through which the electrical conductor extends to couple the control module and the power source module.
  • the components may comprise control electronics that control the functioning of the IMD.
  • nonhermetic batteries are not used in IMDs due to the potential hazard to the components within the IMD.
  • the nonhermetic battery may leak substances that contain corrosive compounds, such as vaporized organic solvents, gasses produced during operation of the battery, and liquid electrolytes including salts.
  • the substances may move from the nonhermetic battery to the components within the IMD where the corrosive compounds could cause damage.
  • the damage would not only be harmful to the IMD, but could potentially be harmful to a patient in whom the IMD is implanted.
  • the substances from the nonhermetic battery that contain corrosive compounds may enter the patient's body.
  • An embodiment of the invention described herein includes a barrier within the IMD to substantially impede movement of substances from the nonhermetic battery to the components.
  • the barrier may include, for example, a hermetic feedthrough through which the electrical conductor extends, a gel, a polymer, or a solid electrolyte within the nonhermetic battery, and a seal member.
  • the barrier may also be a material that encapsulates the nonhermetic battery and a getter within a housing of the power source module.
  • a getter is a material which, when used in a closed container, absorbs or reacts with the substance in the container to neutralize the substance.
  • a getter may be a getter for one substance and may not have any effect upon another substance.
  • the barrier may include a material that fills at least a portion of a void defined by the interconnect member and a getter within the interconnect member or the control module housing.
  • the length and/or the cross-sectional area of the interconnect member may also act as a barrier; in some embodiments the interconnect member is crimped to create a reduced-cross-sectional area region that serves to restrict the movement of substances.
  • the IMD may include one of the barriers listed above or any combination of the barriers to impede the movement of substances from the nonhermetic battery.
  • the invention is directed to an implantable medical device comprising components and a power source module.
  • the power source module includes a nonhermetic battery.
  • An electrical conductor delivers power from the nonhermetic battery to the components.
  • a " barrier that substantially impedes movement of substances from the nonhermetic battery to the components is located between the components and the nonhermetic battery.
  • the invention is directed to an implantable medical device comprising components and a power source module.
  • the power source module includes a power source module housing and a nonhermetic battery within the power source module housing.
  • An electrical conductor delivers power from the nonhermetic battery to the components.
  • a material that substantially impedes movement of substances from the nonhermetic battery to the components is included within the power source module housing.
  • the invention is directed to an implantable medical device comprising components and a power source module.
  • the power source module includes a nonhermetic battery.
  • An electrical conductor delivers power from the nonhermetic battery to the components.
  • a means for substantially impeding movement of substances from the nonhermetic battery to the components is included in the implantable medical device.
  • the invention is directed to an implantable medical device comprising a control module and a power source module.
  • the control module includes a control module housing and components within the control module housing.
  • the power source module includes a power source module housing and a nonhermetic battery within the power source module housing.
  • An interconnect member couples the control module and the power source module.
  • An electrical conductor extends through the interconnect member from the nonhermetic battery to the components to deliver power from the nonhermetic battery to the components.
  • the invention is directed to a method of manufacturing an implantable medical device. The method comprises forming a control module including components and forming a control module housing to house the components.
  • the method further comprises forming a power source module including a nonhermetic battery and forming a power source module housing to house the nonhermetic battery.
  • the method also comprises forming an interconnect member to couple the control module and the power source module.
  • the interconnect member includes an electrical conductor that extends through the interconnect member to deliver power from the nonhermetic battery to the components.
  • the invention may be capable of providing one or more advantages.
  • a barrier that substantially impedes movement of substances from the nonhermetic battery to the components allows the nonhermetic battery to be used safely within the IMD.
  • One or more barriers block, absorb, and/or dissipate the corrosive compounds included in the substances, thereby preventing damage to the components and harm to the patient in which the IMD is implanted.
  • the nonhermetic battery within the IMD may provide a number of advantages relative to a hermetic battery.
  • the nonhermetic battery may permit significant reductions in the thickness of the power source module housing and the overall profile of the IMD as well as a reduction in the overall size of the IMD.
  • the reduced size and profile thickness allows the IMD to be more cosmetically appealing, comfortable, and clinically acceptable when implanted within a patient.
  • the IMD may create a much smaller and less noticeable protrusion when implanted in the patient, and may reduce the likelihood of skin erosion above the implanted IMD.
  • the nonhermetic battery may have increased longevity and energy density per cubic centimeter when compared to hermetic batteries.
  • the thin nonhermetic battery may also increase packaging efficiency. A much larger choice of materials are available for the nonhermetic battery than for a hermetic battery. A wider variety of battery form factors are also possible, including the potential to use a foil-pack flexible battery.
  • the reduced packaging and variety of material choices associated with the nonhermetic battery significantly reduces the cost of manufacturing the IMD, potentially by as much as ten times relative to some existing IMDs.
  • FIG. 1 is a conceptual diagram illustrating an example implantable medical device (IMD) implanted on a cranium of a patient.
  • IMD implantable medical device
  • FIG. 2 is a top-view diagram further illustrating the IMD from FIG. 1 implanted on the cranium of the patient.
  • FIG. 3 is a top-view diagram further illustrating a modular IMD.
  • FIG. 4 is a block diagram illustrating a control module of the modular IMD
  • FIG 5 is a block diagram illustrating a power source module of the modular
  • FIGS. 6-11 are block diagrams illustrating example IMDs including barriers to substantially impede movement of substances from a nonhermetic battery in accordance with various embodiments of the invention.
  • FIG. 12 is a block diagram illustrating a top view of another example IMD.
  • FIG. 1 is a conceptual diagram illustrating an example implantable medical device (IMD) 10 that includes a power source module and a nonhermetic battery housed within a power source module housing.
  • the nonhermetic battery may reduce a thickness and overall size of the power source module housing and thereby reduce a profile of IMD 10.
  • the reduced profile allows IMD 10 to be more cosmetically appealing, comfortable, and clinically acceptable when implanted, for example, on the cranium 12 of a patient 14.
  • IMD 10 permit the device to be implanted at many other locations within the body of patient 14 that do not present an adequate profile for conventional implantable medical devices.
  • the nonhermetic battery may provide advantages beyond the reduced profile of IMD 10. For example, compared to a hermetic battery, the nonhermetic battery expands the material and form factor choices available for the power source module housing. Increased packaging efficiency and the ability to select less expensive materials allows the nonhermetic battery to significantly reduce the cost of manufacturing IMD 10. In addition, the nonhermetic battery increases longevity and energy density per cubic centimeter. [0028] In general, a nonhermetic battery is built to perform substantially similar to a hermetic battery. For example, a nonhermetic battery may initially perform just as well in a helium leak test as a hermetic battery.
  • nonhermetic batteries typically have enclosures that include crimped seals. Over time, the crimped seals have a tendency to break down and leak substances, such as vaporized organic solvents, gasses produced during operation of the battery, and liquid electrolytes including salts.
  • IMD 10 includes a barrier to substantially impede the movement of substances from the nonhermetic battery to components in IMD 10.
  • the barrier ensures that the substances from the nonhermetic battery will not harm patient 14 in which IMD 10 is implanted and will not damage the components.
  • the components comprise control electronics that control the functioning of the IMD.
  • the nonhermetic battery can be applied within an IMD of any structure.
  • the invention will be described herein as a modular IMD housed in a member that at least partially encapsulates one or more housings of the modules and, and generally serves to provide a smooth interface between the modules and the body tissue.
  • IMD 10 comprises a plurality of separately housed and flexibly interconnected modules. By distributing components of IMD 10 among modules rather than including them within a single, rigid housing, the IMD may be shaped and configured for implantation at locations within patient 14 for which implantation of conventional IMDs is deemed undesirable or inapplicable.
  • modular IMD 10 is coupled to two leads 16A and 16B (collectively "leads 16") that extend through holes within cranium 12, and into the brain of patient 14.
  • leads 16 carries a plurality of electrodes
  • IMD 10 delivers stimulation to the brain of patient 14 via the electrodes.
  • Modular IMD 10 may be coupled to any number of leads 16, and in some embodiments is not coupled to any leads 16. In some embodiments, for example, IMD 10 may carry integrated electrodes.
  • FIG. 2 is a top- view diagram further illustrating IMD 10 implanted on cranium 12 of the patient 14.
  • an incision 20 is made through the scalp of patient 14, and a resulting flap of skin is pulled back to expose the desired area of cranium 12.
  • the incision may, as shown in FIG. 2, be generally shaped like a "C.” Such an incision is commonly referred to as a "C-flap" incision.
  • Holes 22A and 22B are drilled through cranium 12, and leads 16 are inserted through holes 22 and into the brain of patient 14. Caps such as burr hole caps may be placed over holes 22 as is known in the art. Leads 16 are connected to modular IMD 10, either directly or via a lead extension, and modular IMD 10 is placed at least partially within a pocket formed using a hand or a tool beneath the scalp behind holes 22.
  • modular IMD 10 may then be fixed to cranium 12 using an attachment mechanism such as bone screws.
  • the skin flap may be closed over modular IMD 10, and the incision may be stapled or sutured.
  • the location on cranium 12 at which IMD 10 is illustrated as implanted in FIG. 2 is merely exemplary, and IMD 10 can be implanted anywhere on the surface of cranium 12.
  • the IMD may be manipulated during implantation such that it conforms to cranium 12.
  • a surgeon can manipulate modular IMD 10 into conformance with cranium 12 while IMD 10 is on cranium 12 and fix modular IMD 10 into place using bone screws or the like.
  • the clinician may manipulate modular IMD 10 into conformance with cranium 12 with IMD 10 on and/or off of cranium 12, and IMD 10 may substantially retain the form into which it is manipulated.
  • modular IMD 10 may deliver stimulation to the brain of patient 14 to, for example, provide deep brain stimulation (DBS) therapy, or to stimulate the cortex of the brain.
  • DBS deep brain stimulation
  • Cortical stimulation may involve stimulation of the motor cortex.
  • Modular IMD 10 may be used to treat any nervous system disorder including, but not limited to, epilepsy, pain, psychological disorders including mood and anxiety disorders, movement disorders (MND), such as, but not limited to, essential tremor, Parkinson's disease, and neurodegenerative disorders.
  • DBS deep brain stimulation
  • MND movement disorders
  • modular IMD 10 is not limited to delivery of stimulation to the brain of patient, and may be employed with leads 16 deployed anywhere in the head or neck including, for example, leads deployed on or near the surface of the skull, leads deployed beneath the skull such as near or on the dura mater, leads placed adjacent cranial or other nerves in the neck or head, or leads placed directly on the surface of the brain.
  • modular IMD 10 is not limited to implantation on cranium 12. Indeed, modular IMD 10 may be implanted anywhere within patient 14. For example, modular IMD 10 can be implanted within the neck of patient 14, and deliver stimulation to the vagus nerve or the cervical region of the spinal cord.
  • Modular IMD 10 may alternatively be implanted within a pectoral region or the abdomen of patient 14 to act as a diaphragmatic pacer, or to provide any of the monitoring and therapy delivery functions known in the art to be associated with cardiac pacemakers. Further, modular IMD 10 may be implanted in the upper buttock region and deliver spinal cord, urological or gastrological stimulation therapy, or may be configured to be implanted within the periphery, e.g., limbs, of patient 14 for delivery of stimulation to the muscles and/or peripheral nervous system of patient 14. Additional implant locations may include the abdomen, e.g., for gastric stimulation.
  • Modular IMD 10 may enable implantation at some of these example locations for which implantation of conventional IMDs is generally deemed undesirable.
  • Modular IMD 10 is not limited to embodiments that deliver stimulation.
  • modular IMD 10 may additionally or alternatively monitor one or more physiological parameters and/or the activity of patient 14, and may include sensors for these purposes.
  • modular IMD 10 may operate in an open loop mode (also referred to as non-responsive operation), or in a closed loop mode (also referred to as responsive). Modular IMD 10 may also provide warnings based on the monitoring.
  • Shorter leads 16 may advantageously improve the accuracy of such sensors by reducing noise attributable to leads 16. Shorter leads 16 may also advantageously reduce the negative affects of imaging techniques such as magnetic resonance imaging "MRI" on a person implanted with IMD 10. Within an MRI machine, leads act as antennas positioned very close to an antenna tower, therefore using shorter leads 16 reduces an amount of energy induced onto IMD 10 from the MRI machine.
  • imaging techniques such as magnetic resonance imaging "MRI"
  • modular IMD 10 can additionally or alternatively deliver a therapeutic agent to patient 14, such as a pharmaceutical, biological, or genetic agent.
  • Modular IMD 10 may be coupled to a catheter, and may include a pump to deliver the therapeutic agent via the catheter.
  • FIG. 3 is a top-view diagram further illustrating modular IMD 10.
  • modular IMD 10 includes three modules: a control module 30, a power source module 32, and a recharge module 34. As shown in FIG. 3, modules 30, 32 and 34 include separate housings 36, 38 and 40, respectively.
  • Control module 30 includes components within the housing.
  • the components comprise control electronics, e.g., electronics that control the monitoring and/or therapy delivery functions of modular IMD 10, such as a microprocessor.
  • Control module 30 may also include circuits for telemetry communication with external programmers or other devices within the housing.
  • Housing 36 of control module 30 may be hermetic in order to protect the components therein, and in exemplary embodiments is formed of a rigid material, such as titanium, stainless steel, or a ceramic.
  • housing 36 is a low-profile, concave housing to substantially conform to a patient's cranium.
  • Power source module 32 includes a nonhermetic battery.
  • a nonhermetic battery is a battery contained within a nonhermetic housing or other nonhermetic enclosure, e.g., a housing or enclosure, as described above. The nonhermetic battery is then further housed within housing 38. The nonhermetic battery provides power for components of other modules, such as the components within control module 30.
  • the nonhermetic battery may be any nonhermetic battery suitable for use within an IMD.
  • the nonhermetic battery comprises a rechargeable Lithium Ion battery with a flexible foil pack construction to more easily fit within housing 38, which may be less than approximately 5 millimeters thick in a direction normal to a major plane of the housing.
  • housing 38 may include an approximately one square inch (6.5 square centimeters) surface area.
  • Housing 38 may be hermetic, and may be formed of titanium, stainless steel, or a ceramic.
  • Power source module 32 may include an insulator within housing 38 to electrically isolate housing 38 from the nonhermetic battery.
  • IMD 10 including the nonhermetic battery has a maximum thickness of between approximately 1 millimeter and approximately 5 millimeters. The use of a reduced profile may reduce the risk of infection, skin erosion and cosmetic issues related to the implantation of IMD 10.
  • modular IMD 10 may include recharge module 34.
  • Recharge module 34 includes a recharge coil (not shown) within housing 40.
  • the recharge coil inductively receives energy from an external recharging unit (not illustrated) through the skin of patient 14 to recharge the nonhermetic battery.
  • the recharge coil may be formed of windings of copper or another highly conductive material.
  • Housing 40 need not be heraietic, and may be formed of materials such as silicone, polymers and ceramics.
  • Housings 36, 38 and 40 may have any shape, including the round, coin shape and rectangular shapes with rounded edges illustrated in FIG. 3. Further, one or more surfaces of one or more of housings 36, 38 and 40 may be concave along at least one axis, and preferably two axes.
  • Modules 30, 32 and 34 can be configured in a variety of ways, and the configuration illustrated in FIG. 3 is merely exemplary. Further, modular IMD 10 can include any number of modules, and may include other types of modules instead of or in addition to a control module 30 and a recharge module 34. For example, modular IMD 10 can include a module within another module, such as power source module 32 within control module 30. In addition, modular IMD 10 can include additional power source modules, modules that include additional memory that is accessible by the components, modules that include reservoirs for storing therapeutic agents and pumps for delivering therapeutic agents to patient 14, and modules that include sensors sensing physiological parameters, such as pressures or blood flows, or the activity level of patient 14.
  • Power source module 32 is coupled to control module 30 by a flexible interconnect member 44, which encloses an electrical conductor that allows transmission of energy from the nonhermetic battery of power source module 32 to components such as the components within control module 30.
  • a flexible interconnect member 44 may be made of titanium, stainless steel, or nitinol.
  • flexible interconnect member 44 need not be hermetic, and may be made of any material including silicone or various polymers.
  • control module 30 regulates the recharging and discharging of the nonhermetic battery within power source module 32. Consequently, as shown in FIG. 3, recharge module 34 is coupled to control module 30 by a flexible interconnect member 46 that encloses an electrical conductor that allows transmission of energy inductively received by the recharge coil within recharge module 34 to control module 30. Because the energy is transferred on the electrical conductor via a charge-balanced voltage, flexible interconnect member 46 need not be hermetic, and may be made of any material including titanium, stainless steel, nitinol, ceramics, silicone or various polymers.
  • Interconnect members 44 and 46 are flexible. In some embodiments, as indicated above, interconnect members 44 and 46 are made of a flexible material such as silicone, a flexible polymer, or nitinol. In embodiments where flexible member 44 is hermetic and made of a substantially less flexible material, such as titanium or stainless steel, the flexibility of interconnect member 44 is provided by the configuration and/or construction of flexible interconnect member 44. [0053] Interconnect member 44 is flexible in a plurality of directions to provide modules 30 and 32 with multiple degrees of freedom of motion with respect to each other. In exemplary embodiments, interconnect member 44 provides at least three degrees of motion, and the degrees of motion provided include rotational motion.
  • modular IMD 10 includes a member 48, which may be flexible and made of a soft biocompatible material.
  • Member 48 at least partially encapsulates one or more of housings 36, 38 and 40, and generally serves to provide a smooth interface between the modules and the body tissue.
  • Member 48 may integrate modules 30, 32 and 34 into a desired form factor, but, where flexible, allow relative intermodule motion.
  • member 48 incorporates mechanical features to restrict intermodule motion to certain directions or within certain ranges.
  • Member 48 may be made from silicone, and in some embodiments may be made from two or more materials of differing flexibility, such as silicone and a polyurethane.
  • Member 36 may also be referred to as an "overmold,” but use of the term “overmold” herein is not intended to limit the invention to embodiments in which member 36 is a molded structure.
  • Member 36 may be a molded structure, or may be a structure formed by any process.
  • Member 48 can be shaped to contour to cranium 12, e.g., may be concave along at least one axis, and may be contoured at its edges to prevent skin erosion on the scalp of patient 14. The flexibility and shape of member 48 may, in some embodiments, improve the comfort and cosmetic appearance of modular IMD 10 under the scalp, and may make IMD 10 more clinically acceptable by, for example, reducing the likelihood of skin erosion.
  • modular IMD 10 also includes lead connector modules 50A and 50B (collectively “lead connector modules 50") formed within member 48 to receive leads 16 or lead extensions coupled to leads 16. Conductors 52 extend from lead connector modules 50 to hermetic feedthroughs (not illustrated) within housing 36 of control module 30. Lead connector modules 50 may be formed anywhere within member 48. In embodiments where member 48 includes a rigid material in addition to a flexible material, the rigid material may form at least part of lead connector modules 50 to secure leads 16 or lead extensions, and to protect conductors 52 from damage that may result from flexing within member 48.
  • FIG. 4 is a block diagram illustrating control module 30 of modular IMD 10.
  • control module 30 includes components, such as control electronics that control the functioning of modular IMD 10 within housing 36.
  • the components include a processor 60, which may take the form of a microprocessor, digital signal processor (DSP), application specific integrated circuit (ASIC), field- programmable gate array (FPGA), or other logic circuitry.
  • DSP digital signal processor
  • ASIC application specific integrated circuit
  • FPGA field- programmable gate array
  • Control module 30 also includes a memory 62, such as a read-only memory (ROM), random access memory (RAM), electronically-erasable programmable ROM (EEPROM), flash memory, or the like.
  • Memory 62 may store program instructions that may be executed by processor 60 and thereby control the functioning of modular IMD 10.
  • control module 30 includes telemetry circuitry 64, which enables processor 60 to communicate with other devices such as an external programming device via radio-frequency communication.
  • Telemetry circuitry 64 may include a telemetry coil (not illustrated), which may be fabricated of windings of copper or another highly conductive material. The configuration and location of the telemetry coil within housing 36 may be dictated by the available space within housing 36 and the communication requirements of telemetry circuitry 64.
  • modular IMD 10 delivers electrical stimulation, and more particularly, control module 30 includes therapy delivery circuitry 66 within housing 36 that generates electrical stimulation.
  • therapy delivery circuitry 66 comprises circuits for the generation of electrical stimulation in the form of pulses, such as capacitors and switches.
  • therapy delivery circuitry 66 may deliver the pulses to a switch matrix 68, which comprises an array of switches.
  • processor 60 interacts with switch matrix 68 to select electrodes for delivery of generated stimulation pulses. Based on the selections made by processor 60, switch matrix 68 delivers the pulses to conductors that pass through feedthroughs in housing 36 and to electrical contacts on leads 16 that are electrically coupled to the desired electrodes carried by leads 16.
  • control module 30 receive energy from the nonhermetic battery within power source module 32 via interconnect member 44 (FIG. 3).
  • control module 30 receives energy inductively captured by recharge module 34 via interconnect member 46, and includes power management circuitry 70 that controls the recharging and discharging of the nonhermetic battery.
  • Power management circuitry 70 may ensure that the nonhermetic battery is not overcharged, over-discharged, or harmed.
  • power management circuitry 70 includes circuits to measure voltages, currents or temperatures associated with the nonhermetic battery, or rates of change of these parameters, and controls recharging and discharging according to the measured values.
  • Power management circuitry 70 may also include circuits, such as rectifier circuits, for converting charge-balanced voltages, e.g., AC voltages, provided by a recharge coil (not shown) into net DC voltages for recharging the nonhermetic battery.
  • circuits such as rectifier circuits, for converting charge-balanced voltages, e.g., AC voltages, provided by a recharge coil (not shown) into net DC voltages for recharging the nonhermetic battery.
  • FIG. 5 is a block diagram illustrating power source module 32 of modular IMD 10.
  • Power source module 32 includes a rechargeable nonhermetic battery 72 within housing 38.
  • power source module 32 also includes power management circuit 74 that controls the recharging and discharging of nonhermetic battery 72.
  • power management circuitry 74 may ensure that nonhermetic battery 72 is not overcharged, over-discharged, or harmed.
  • power management circuitry 74 includes circuits to measure voltages, currents or temperatures associated with nonhermetic battery 72, or rates of change of these parameters, and controls recharging and discharging of nonhermetic battery 72 according to the measured values.
  • Power management circuitry 74 may also include circuits, such as rectifier circuits, for converting charge-balanced voltages, e.g., AC voltages, provided by a recharge coil (not shown) into DC voltages for recharging nonhermetic battery 72.
  • power management circuitry 74 includes modulating circuits, i.e., circuits that enable power management circuit 74 to deliver energy to control module 30 in the form of charge-balanced voltages on an electrical conductor.
  • control module 30 includes circuits, such as rectifier circuits, to convert the charge- balanced voltages to DC voltages for use by components of control module 30.
  • FIGS. 6-11 are block diagrams illustrating example IMDs including barriers, in accordance with embodiments of the invention, that substantially impede movement of substances from a nonhermetic battery to components within the example IMDs.
  • the components comprise control electronics.
  • the substances from the nonhermetic battery may contain corrosive compounds, such as vaporized organic solvents, gasses produced during operation of the battery, and liquid electrolytes including salts.
  • the barriers impede the movement of substances from the nonhermetic battery to the components so that the corrosive compounds cannot cause damage. The damage would not only be harmful to the IMD, but could potentially be harmful to a patient in whom the IMD is implanted.
  • the substances from the nonhermetic battery that contain corrosive compounds may enter the patient's body.
  • the damaged IMD may malfunction, e.g., abruptly quit delivering therapy or deliver inappropriate therapy to the patient.
  • each of the barriers may be used individually or in combination with one another.
  • each of the IMDs illustrated in FIGS. 6-11 comprises one electrical conductor between the nonhermetic battery and the components.
  • at least two electrical conductors are included to allow electrical isolation between a housing of the nonhermetic battery and a case of the IMD.
  • the case of the IMD may be used as an electrical element for interaction with an electrode, for example.
  • the invention may be included in an IMD of any structure, but will be described herein as embodied within a modular IMD.
  • FIGS. 6A and 6B are block diagrams illustrating a top view and a side view, respectively, of an example IMD 78.
  • IMD 78 includes a power source module 80 that includes a power source module housing 81 and a nonhermetic battery 84 within power source module housing 81. Additionally, IMD 78 further includes a control module 82 that includes a control module housing 83 and components 86 within control module housing 83. An electrical conductor 88 extends from nonhermetic battery 84 to components 86 and delivers power from nonhermetic battery 84 to components 86. Power source module 80 and control module 82 are coupled via an interconnect member 90, through which conductor 88 extends.
  • IMD 78 comprises a hermetic feedthrough 92 that acts as a barrier to substantially impede movement of substances, such as vaporized organic solvents, gasses produced during operation of the battery, and liquid electrolytes including salts, from nonhermetic battery 84 to components 86.
  • Electrical conductor 88 extends through hermetic feedthrough 92 between nonhermetic battery 84 and components 86.
  • hermetic feedthrough 92 is positioned at an interface area 93 where power source module 80 and interconnect member 90 couple to each other. In that way, hermetic feedthrough 92 may ensure that no corrosive compounds included in the substances from nonhermetic battery 84 can leave power source module housing 81.
  • a hermetic feedthrough comprises a weld or a braise that maintains a substantially permanent air-tight seal.
  • hermetic feedthrough 92 blocks the movement of substances from reaching components 86, at least a portion of hermetic feedthrough 92 is exposed to the corrosive compounds within the substances.
  • the exposed portion of hermetic feedthrough 92 may be subject to corrosive effects, especially at contact points with power source module housing 81 and nonhermetic battery 84. Therefore, in order to connect hermetic feedthrough 92 to the positive pole of nonhermetic battery 84, a selected pin material must be able to avoid corrosion.
  • a Niobium pin may be prone to corrosion, but suitable corrosion- resistant pin materials may include Ti-6V-4A1, aluminum, or molybdenum.
  • hermetic feedthrough 92 may comprise a suitable corrosion-resistant feedthrough glass material, such as Cabal- 12.
  • interconnect module 90 is a conductor in electrical contact with one of the poles of nonhermetic battery 84.
  • additional hermetic feedthroughs may be included in IMD 78.
  • interconnect member 90 can be electrically insulated from nonhermetic battery 84.
  • Additional feedthroughs may also be used to connect control module 82 to sensors in power source module 80. The sensors may detect temperature or, in the case of a voltage reference electrode, battery status.
  • Hermetic feedthrough 92 forms apart of power source module housing 81.
  • FIGS. 7A and 7B are block diagrams illustrating a top view and a side view, respectively, of another example IMD 94.
  • IMD 94 includes a power source module 96 that includes a power source module housing 97 and a nonhermetic battery 100 within power source module housing 97.
  • IMD 94 further includes a control module 98 that includes a control module housing 99 and components 102 within control module housing 99.
  • An electrical conductor 104 extends from nonhermetic battery 100 to components 102 and delivers power from nonhermetic battery 100 to components 102.
  • Power source module 96 and control module 98 are coupled via an interconnect member 106, through which conductor 104 extends.
  • IMD 94 comprises a hermetic feedthrough 108 that acts as a barrier to substantially impede movement of substances from nonhermetic battery 100 to components 102.
  • Electrical conductor 104 extends through hermetic feedthrough 108 between nonhermetic battery 100 and components 102.
  • hermetic feedthrough 108 is positioned at an interface area 109 where interconnect member 106 and control module 98 couple to each other. In that way, hermetic feedthrough 108 may ensure that no corrosive compounds included in the substances from nonhermetic battery 100 can enter control module housing 99.
  • Hermetic feedthrough 108 may be substantially similar to hermetic feedthrough 92 described in reference to FIGS. 6 A and 6B.
  • Hermetic feedthrough 108 forms a part of control module housing 99. However, hermetic feedthrough 108 in control module housing 99 causes interface area 109 of interconnect member 106 to comprise a thickness at least as thick as an outside cross-sectional area of hermetic feedthrough 92. As shown in FIG. 7B, power source module housing 97 and interconnect member 106, until interface area 109, comprise thicknesses less than an outside area of hermetic feedthrough 108.
  • a hermetic feedthrough may be located at any position along an interconnect member, such as interconnect member 106.
  • the interconnect member may be constructed in two sections joined together by, for example, welding. Movement of substances from a nonhermetic battery may subject the welded areas of the interconnect member to corrosive effects.
  • the hermetic feedthrough may be positioned between the two sections to block the movement of substances from . damaging the welded areas of the interconnect member and components within the IMD.
  • FIG. 8 is a block diagram illustrating a top view of an example IMD 110.
  • IMD 110 includes a power source module 112 that includes a power source module housing 113 and a nonhermetic battery 116 within power source module housing 113. Additionally, IMD 110 further includes a control module 114 that includes a control module housing 115 and components 118 within control module housing 115. An electrical conductor 120 extends from nonhermetic battery 116 to components 118 and delivers power from nonhermetic battery 116 to components 118. Power source module 112 and control module 114 are coupled via an interconnect member 122, through which conductor 120 extends.
  • IMD 110 comprises a first seal member 124 and a second seal member 126 that act as barriers to substantially impede movement of substances from nonhermetic battery 116 to components 118.
  • First seal member 124 is positioned within interconnect member 122 where interconnect member 122 couples to power source module 112.
  • First seal member 124 blocks the movement of substances from leaving the power source module housing 113.
  • Second seal member 126 is positioned within interconnect member 122 where interconnect member 122 couples to control module 114. Second seal member 126 blocks the movement of substances from entering the control module housing 115.
  • first and second seals 124, 126 may comprise o-ring, gasket, or grommet seals.
  • only one of the first and second seal members is included within IMD 110.
  • a plurality of seal members may be positioned at a plurality of locations within IMD 110.
  • First and second seals 124, 126 may comprise materials with low permeability and high creep resistance.
  • these materials may be cross-linked crystalline materials that are either rigid or elastomeric.
  • a partial list of rigid materials includes polypropylene, high density polyethylene, polyester, and engineering plastics such as polymers containing ether ketones (PEK, PEEK), polyether imide (PEI), polyamide imide (PAI), polyphenylene oxide (PPO), polyether sulfone (PES), and polyphenylene sulfide (PPS).
  • FIG. 9 is a block diagram illustrating a top view of an example IMD 128.
  • IMD 128 includes a power source module 130 that includes a power source module housing 131 and a nonhermetic battery 134 within power source module housing 131. Additionally, IMD 128 further includes a control module 132 that includes a control module housing 133 and components 136 within control module housing 133. An electrical conductor 138 extends from nonhermetic battery 134 to components 136 and delivers power from nonhermetic battery 134 to components 136. Power source module 130 and control module 132 are coupled via an interconnect member 140, through which conductor 138 extends. Interconnect member 140 may define a void through which electrical conductor 138 extends.
  • the void of interconnect member 140 is filled with a material 141 to substantially impede movement of substances from nonhermetic battery 134 to components 136.
  • the interconnect member void is only partially filled with material 141.
  • Material 141 may be one of backfilled, flowed, and inserted into the void of interconnect member 140. In the case where material 141 is inserted into the void, material 141 may be manipulated after insertion to create a substantially permanent air-tight seal with interconnect member 141. Material 141 is substantially impermeable to the substances from nonhermetic battery 134.
  • material 141 blocks corrosive compounds within the substances from reaching components 136 and potentially damaging IMD 128 and injuring a patient in which IMD 128 is implanted.
  • Material 141 may also be flexible to allow interconnect member 140 to bend and flex, as described above.
  • a suitable material 141 may include a thermoplastic polymer such as polyolefin or ethylvinyl acetate.
  • Material 141 may also comprise a thermosetting resin introduced to interconnect member 140 in a liquid or molten state and cured after filling. Examples of thermosetting resins include epoxies, silicones, polyurethanes, and isocyanates.
  • material 141 comprise a material that expands, or at least minimally contracts, upon solidification.
  • material 141 may comprise a closed-cell foam that forms a gas upon curing such as isocyanate-terminated polyurethanes and acrylic latex polymers. Isocyanates, which have the property of forming strong bonds to metals such as aluminum, are therefore useful for forming a tight, permanent seal within interconnect member 140.
  • Material 141 may also include fillers that may be in a finely divided form such as flakes or powders. Fillers may either impart low permeability or absorption of the substances from nonhermetic battery 134. Absorbents may include getters described in more detail below. Materials with low permeability may include minerals, e.g., mica, ceramics, metals, and polymers. Material 141 may comprise a nonconductive metal, such as aluminum. If material 141 includes metals that would render material 141 electrically conductive, then nonhermetic battery 134 may require a complete or partial layer of electrical insulation from material 141.
  • FIG. 10 is a block diagram illustrating a top view of an example IMD 142.
  • IMD 142 includes a power source module 144 that includes a power source module housing 145 and a nonhermetic battery 148 within power source module housing 145. Additionally, IMD 142 further includes a control module 146 that includes a control module housing 147 and components 150 within control module housing 147.
  • An electrical conductor 152 extends from nonhermetic battery 148 to components 150 and delivers power from nonhermetic battery 148 to components 150.
  • Power source module 144 and control module 146 are coupled via an interconnect member 154, through which conductor 152 extends.
  • Power source control module 144 includes a material 156 that substantially encapsulates nonhermetic battery 148 within power source module housing 145. In some embodiments, material 156 may only partially encapsulate nonhermetic battery 148. Encapsulating nonhermetic battery 148 within material 156 substantially blocks movement of substances from leaving power source module housing 145. Material 156 is impermeable by corrosive compounds included in the substances from nonhermetic battery 148. The substances typically move out of nonhermetic battery 148 along termination wires or joints between sections of a battery case (not shown) or between the battery case and a nonhermetic feedthrough. Specifically designing material 156 to be resistant to the movement of substances from nonhermetic battery 148 at those locations increases containment of the corrosive compounds that may harm components 150 and a patient in which IMD 142 is implanted.
  • nonhermetic battery 148 may be polymerized in place within power source module housing 145 with material 156.
  • material 156 may comprise a thermosetting plastic, such as silicone, epoxy, or polyester.
  • material 145 may comprise a thermoplastic that, when melted, flows into power source module housing 145 to surround nonhermetic battery 148.
  • material 145 may comprise a polyolefin, which includes polyethylene and polypropylene.
  • material 145 may comprise one of the materials listed above for seal members 124 and 126 (FIG. 8) and material l41 (FIG. 9).
  • FIG. 11 is a block diagram illustrating a top view of an example IMD 158.
  • IMD 158 includes a power source module 160 that includes a power source module housing 161 and a nonhermetic battery 164 within power source module housing 161. Additionally, IMD 158 further includes a control module 162 that includes a control module housing 163 and components 166 within confrol module housing 163. An electrical conductor 168 extends from nonhermetic battery 164 to components 166 and delivers power from nonhermetic battery 164 to components 166. Power source module 160 and control module 162 are coupled via an interconnect member 170, through which conductor 168 extends.
  • interconnect member 170 The movement of substances may be impeded by a length and/or cross- sectional area of interconnect member 170.
  • a long interconnect member allows the substances from nonhermetic battery 164 to dissipate before reaching components 166.
  • a small interconnect member cross-sectional area increases resistance against the movement to slow the diffusion rate of the substances from nonhermetic battery 164 to components 166.
  • the ratio of interconnect member length to internal area should be kept as large as possible to increase diffusional resistance.
  • interconnect member 170 comprises a cylindrical shape
  • the ratio of interconnect member length to outside diameter is at least 10.
  • an interconnect member length of 3 inches and an outside diameter of 0.05 inch gives a ratio of 60.
  • the interconnect member ratio may also be applied to any of the IMDs described above.
  • interconnect member 170 is crimped to create reduced-area regions 172 that substantially impede movement of substances from nonhermetic battery 164 to components 166. Crimping interconnect member 170 may involve pinching, rolling, drawing, or a combination thereof. In other embodiments, a plurality of reduced-area regions may be created along the length of interconnect member 170.
  • a void defined by interconnect member 170 is at least partially filled with a material, substantially similar to FIG. 9. Reduced- cross-sectional area regions 172 are created after placing the material within the void of interconnect member 170. The material creates a pressure seal within interconnect member 170 at each reduced-cross-sectional area region 172.
  • IMD 158 may also include a getter to substantially impede the movement of substances from nonhermetic battery 164 to components 166.
  • the getter may be located within at least one of power source module 160, interconnect member 170, and confrol module 162.
  • the getter absorbs or reacts with the substances within IMD 158 to form a solid nonvaporizable material or to substantially eliminate the corrosive compounds and/or elements that create corrosive compounds included in the substances from nonhermetic battery 164.
  • several getters are included in IMD 158.
  • the getter may also be included within any of the IMDs described above.
  • the getter may comprise a desiccant, or any other type of getter for water.
  • desiccants are silica gel or calcium carbonate, silico-aluminate, clay (montmorillonite), and molecular sieve. If PF 6 leaks out of nonhermetic battery 164 and water is available, the compounds will react to produce hydrofluoric acid (HF). However, if no water is available, no HF can be created. If any HF were to come in contact with components 166, it would damage components 166 and potentially injure a patient in which IMD 158 is implanted.
  • HF hydrofluoric acid
  • the getter may also comprise a getter for HF, such as fumed or gelled silica because silica is an excellent HF getter.
  • the getter may further comprise a getter for organics.
  • the organic getter may be a type of carbon such as activated charcoal. Carbon has the ability to be formed and pressed into a specific shape, which allows the organic getter to fit in a variety of positions within IMD 158.
  • the getter may be located anywhere within the volume of IMD 158. Further, the getter may be randomly placed in IMD 158 between nonhermetic battery 164 and components 166. The getter may also be directly incorporated within a material to form elements such as seal members, material to fill interconnect member 170, material to encapsulate nonhermetic battery 164, or the like. For example, Multisorb Incorporated of Buffalo, NY, USA manufactures desiccants in forms that may incorporate easily within IMD 158, including machinable material, hot-melt glue, and plastic films.
  • nonhermetic battery 164 may include a gel, polymer, or solid electrolyte instead of a gas or liquid electrolyte.
  • the gel, polymer, or solid electrolyte acts as a barrier within nonhermetic battery 164 by substantially eliminating movement of substances from nonhermetic battery 164.
  • the gel, polymer, or solid electrolyte reduces vapor pressure within nonhermetic battery 164, which reduces a chance of nonhermetic battery 164 leaking.
  • the gel, polymer, or solid electrolyte has a much smaller chance of leaving nonhermetic battery 164 than a gas or fluid electrolyte.
  • An electrolyte gelling agent such as polyvinylidene fluoride (PNDF), polyvinylidene fluoride-hexafluoropropylene (PNDF-HFP) copolymer, polyethylene oxide (PEO), silicon, or a mixture thereof, is used to create the gelled electrolyte.
  • the polymer or solid electrolyte may create a thin- film nonhermetic battery.
  • the solid electrolyte may comprise ceramic or glass.
  • the nonhermetic batteries included in the IMDs described above may also include the gel, polymer, or solid electrolyte.
  • IMD 158 may not include power source module housing 160.
  • nonhermetic battery 164 may couple directly to interconnect member 170 by a hermetic weld or braise around the connection area. Sealing the interface area between nonhermetic battery 164 and interconnect member 170 substantially blocks the substances from entering the patient's body. Eliminating the power source module housing 160 allows IMD 158 to comprise a further reduced profile thickness.
  • the IMDs described above may also not include a power source module housing that fully encapsulates the nonhermetic battery.
  • FIG. 12 is a block diagram illustrating a top view of another example IMD 174.
  • IMD 174 includes a power source module 176 that includes a power source module housing 177 and a nonhermetic battery 180 within power source module housing 177.
  • Control module 178 includes a control module housing 179 and components 182 within control module housing 179.
  • Power source module 176 is included within control module housing 179.
  • An electrical conductor 184 extends from nonhermetic battery 180 to components 182 and delivers power from nonhermetic battery 180 to components 178.
  • components 182 may comprise control electronics.
  • IMD 174 illustrates an IMD set-up as an alternative to the IMDs illusfrated in FIGS. 6-11.
  • the illustrated embodiment may correspond to a non-modular IMD.
  • IMD 174 may comprise a conventional IMD with a single housing that houses substantially all of the IMD's components.
  • the barriers described above may also be applied to IMD 174 to block, absorb and/or dissipate the movement of substances between nonhermetic battery 180 and components 182.
  • an implantable medical device including a nonhermetic battery
  • the nonhermetic battery reduces a profile and a manufacturing cost of the IMD.
  • the IMD also includes a barrier to impede movement of substances from the nonhermetic battery from reaching components within the IMD and injuring a patient in which the IMD is implanted.
  • barriers are described including hermetic feedthroughs, seal members, material to encapsulate the nonhermetic battery, chemical getters, and gel, polymer, or solid electrolytes.
  • a modular IMD is also described that includes an interconnect member to couple a module including the nonhermetic battery to a module including the components. Barriers may also be including in the interconnect member, such as length, cross- sectional area, and material filling at least a portion of a void defined by the interconnect member.
  • the IMD described above may include any nonhermetic electro-chemical generator, such as a fuel cell, instead of a nonhermetic battery.
  • a fuel cell is designed to vent the substances created by operation.
  • the barriers provided by the invention enable a fuel cell or similar generator to be included in an IMD as the barriers substantially impede the movement of substances.
  • the components with the IMD may refer to control electronics as well as sensor control components and other control mechanisms that may or may not be included within the control module housing.

Abstract

An implantable medical device (IMD) including a nonhermetic battery is described. The IMD includes components and a power source module that includes the nonhermetic battery. The IMD also includes a barrier to substantially impede movement of substances from the nonhermetic battery to the components. The barrier may include a hermetic feedthrough, a gel, a polymer, or a solid electrolyte within the nonhermetic battery, and a seal member. The barrier may also be a material that encapsulates the nonhermetic battery and a getter within the IMD. In some embodiments, the IMD comprises a modular IMD including an interconnect member. In that case, the barrier may include a material that fills at least a portion of a void defined by the interconnect member. A length and a cross-sectional area of the interconnect member may also act as a barrier.

Description

IMPLANTABLE MEDICAL DEVICE WITH A NONHERMETIC
BATTERY
[0001] The invention relates to medical devices, and more particularly, to implantable medical devices.
[0002] Depending on the application for which they are implanted in a patient, implantable medical devices (IMDs) may include a variety of electrical and/or mechanical components. Typically, an IMD includes a rigid housing that houses all of its components, which are generally fragile, to protect the components from forces to which they would otherwise be exposed when implanted within the human body. In order to avoid potentially harmful interactions between the components and bodily fluids, e.g., corrosion, IMD housings are typically hermetically sealed. Many IMD housings are fabricated from titanium because of its desirable rigidity and biocompatibility.
[0003] The size and shape of an IMD housing is dependent on the sizes and shapes of the components of the IMD. Large components common to most IMDs include a battery and a circuit board that carries digital circuits, e.g., integrated circuit chips and/or a microprocessor, and analog circuit components. Attempts have been made to reduce the size of the IMD housing by reducing the size of these components, changing the shape of these components, and organizing these components within the IMD housing to avoid empty space within the housing. [0004] However, the functional and safety requirements of IMDs have limited attempts to reduce the size and improve the shape of rigid IMD housings. For example, many types of batteries useful for powering an IMD can emit substances that would be harmful to the patient in which the IMD is implanted and to the other components of the IMD. Consequently, existing IMDs typically use hermetic batteries, e.g., batteries within a hermetically sealed housing or case, as a source of power. However, the need to make the housing or case of the battery hermetic limits the thinness and shapes that the battery may have, e.g., due to need for hermetic feedthroughs and the type of welding required for a hermetic housing or case. These limits to the size and shape that a hermetic battery may have in turn limit the ability of IMD designers to reduce the size and shape of IMD housings. [0005] Consequently, the size, shape and rigidity of IMD housings still greatly limit the locations within the human body where an IMD can be practically implanted. Due to these limitations, an IMD is typically implanted within the abdomen, upper pectoral region, or subclavicular region of a patient. Leads or catheters must be used in order to deliver therapy or monitor a physiological parameter at a location of the body other than where the IMD is implanted. Implantation and positioning of leads and catheters can be difficult and time- consuming from the perspective of a surgeon, particularly where the IMD is located a significant distance from the treatment or monitoring site. Moreover, the increased surgical time, increased surgical trauma, and increased amount of implanted material associated with the use of leads and catheters can increase the risk to the patient of complications associated with the implantation of an IMD. [0006] For example, IMDs that are used to treat or monitor the brain, e.g., to deliver deep brain stimulation (DBS) therapy, are implanted some distance away from the brain, e.g., within the subclavicular region of patients. The long leads that connect the implantable medical device to electrodes implanted within the brain require tunneling under the scalp and the skin of the neck, thereby requiring extensive surgery and a prolonged amount of time under general anesthesia during the implant procedure, as well as increased recovery time. In some cases, tunneling the leads under the scalp and skin of the neck requires an additional surgical procedure under general anesthesia. The lengthy tract along the leads is more susceptible to infection, and the leads can erode the overlying scalp, forcing removal so that the scalp can heal. Further, the long leads running under the scalp and through the neck are more susceptible to fracture due to torsional and other forces caused by normal head and neck movements.
[0007] In general, the invention is directed to an implantable medical device (IMD) including a nonhermetic battery, i.e., a battery that is contained within a nonhermetic housing or other nonhermetic enclosure. The IMD includes components and a power source module that includes the nonhermetic battery. The nonhermetic battery delivers power to the components via an electrical conductor that extends from the nonhermetic battery to the components. In some embodiments the IMD may comprise a modular IMD. In those embodiments, the IMD includes a control module that includes the components within a control module housing and an interconnect member through which the electrical conductor extends to couple the control module and the power source module. In some cases, the components may comprise control electronics that control the functioning of the IMD.
[0008] Conventionally, nonhermetic batteries are not used in IMDs due to the potential hazard to the components within the IMD. The nonhermetic battery may leak substances that contain corrosive compounds, such as vaporized organic solvents, gasses produced during operation of the battery, and liquid electrolytes including salts. The substances may move from the nonhermetic battery to the components within the IMD where the corrosive compounds could cause damage. The damage would not only be harmful to the IMD, but could potentially be harmful to a patient in whom the IMD is implanted. For example, the substances from the nonhermetic battery that contain corrosive compounds may enter the patient's body. In addition, the damaged IMD may malfunction, e.g., and abruptly quit delivering therapy or deliver an inappropriate therapy to the patient. [0009] An embodiment of the invention described herein includes a barrier within the IMD to substantially impede movement of substances from the nonhermetic battery to the components. The barrier may include, for example, a hermetic feedthrough through which the electrical conductor extends, a gel, a polymer, or a solid electrolyte within the nonhermetic battery, and a seal member. The barrier may also be a material that encapsulates the nonhermetic battery and a getter within a housing of the power source module. In general, a getter is a material which, when used in a closed container, absorbs or reacts with the substance in the container to neutralize the substance. A getter may be a getter for one substance and may not have any effect upon another substance. [0010] In embodiments including the control module and the interconnect member, the barrier may include a material that fills at least a portion of a void defined by the interconnect member and a getter within the interconnect member or the control module housing. The length and/or the cross-sectional area of the interconnect member may also act as a barrier; in some embodiments the interconnect member is crimped to create a reduced-cross-sectional area region that serves to restrict the movement of substances. The IMD may include one of the barriers listed above or any combination of the barriers to impede the movement of substances from the nonhermetic battery. [0011] In one embodiment, the invention is directed to an implantable medical device comprising components and a power source module. The power source module includes a nonhermetic battery. An electrical conductor delivers power from the nonhermetic battery to the components. A "barrier that substantially impedes movement of substances from the nonhermetic battery to the components is located between the components and the nonhermetic battery. [0012] In another embodiment, the invention is directed to an implantable medical device comprising components and a power source module. The power source module includes a power source module housing and a nonhermetic battery within the power source module housing. An electrical conductor delivers power from the nonhermetic battery to the components. A material that substantially impedes movement of substances from the nonhermetic battery to the components is included within the power source module housing.
[0013] In another embodiment, the invention is directed to an implantable medical device comprising components and a power source module. The power source module includes a nonhermetic battery. An electrical conductor delivers power from the nonhermetic battery to the components. A means for substantially impeding movement of substances from the nonhermetic battery to the components is included in the implantable medical device.
[0014] In another embodiment, the invention is directed to an implantable medical device comprising a control module and a power source module. The control module includes a control module housing and components within the control module housing. The power source module includes a power source module housing and a nonhermetic battery within the power source module housing. An interconnect member couples the control module and the power source module. An electrical conductor extends through the interconnect member from the nonhermetic battery to the components to deliver power from the nonhermetic battery to the components. [0015] In a further embodiment, the invention is directed to a method of manufacturing an implantable medical device. The method comprises forming a control module including components and forming a control module housing to house the components. The method further comprises forming a power source module including a nonhermetic battery and forming a power source module housing to house the nonhermetic battery. The method also comprises forming an interconnect member to couple the control module and the power source module. The interconnect member includes an electrical conductor that extends through the interconnect member to deliver power from the nonhermetic battery to the components.
[0016] The invention may be capable of providing one or more advantages. For example, a barrier that substantially impedes movement of substances from the nonhermetic battery to the components allows the nonhermetic battery to be used safely within the IMD. One or more barriers block, absorb, and/or dissipate the corrosive compounds included in the substances, thereby preventing damage to the components and harm to the patient in which the IMD is implanted. [0017] The nonhermetic battery within the IMD may provide a number of advantages relative to a hermetic battery. For example, the nonhermetic battery may permit significant reductions in the thickness of the power source module housing and the overall profile of the IMD as well as a reduction in the overall size of the IMD. The reduced size and profile thickness allows the IMD to be more cosmetically appealing, comfortable, and clinically acceptable when implanted within a patient. In particular, the IMD may create a much smaller and less noticeable protrusion when implanted in the patient, and may reduce the likelihood of skin erosion above the implanted IMD. In addition, the nonhermetic battery may have increased longevity and energy density per cubic centimeter when compared to hermetic batteries.
[0018] The thin nonhermetic battery may also increase packaging efficiency. A much larger choice of materials are available for the nonhermetic battery than for a hermetic battery. A wider variety of battery form factors are also possible, including the potential to use a foil-pack flexible battery. The reduced packaging and variety of material choices associated with the nonhermetic battery significantly reduces the cost of manufacturing the IMD, potentially by as much as ten times relative to some existing IMDs.
[0019] FIG. 1 is a conceptual diagram illustrating an example implantable medical device (IMD) implanted on a cranium of a patient.
[0020] FIG. 2 is a top-view diagram further illustrating the IMD from FIG. 1 implanted on the cranium of the patient.
[0021] FIG. 3 is a top-view diagram further illustrating a modular IMD.
[0022] FIG. 4 is a block diagram illustrating a control module of the modular IMD
[0023] FIG 5 is a block diagram illustrating a power source module of the modular
IMD from FIG. 3.
[0024] FIGS. 6-11 are block diagrams illustrating example IMDs including barriers to substantially impede movement of substances from a nonhermetic battery in accordance with various embodiments of the invention.
[0025] FIG. 12 is a block diagram illustrating a top view of another example IMD.
[0026] FIG. 1 is a conceptual diagram illustrating an example implantable medical device (IMD) 10 that includes a power source module and a nonhermetic battery housed within a power source module housing. The nonhermetic battery may reduce a thickness and overall size of the power source module housing and thereby reduce a profile of IMD 10. The reduced profile allows IMD 10 to be more cosmetically appealing, comfortable, and clinically acceptable when implanted, for example, on the cranium 12 of a patient 14. Other embodiments of
IMD 10 permit the device to be implanted at many other locations within the body of patient 14 that do not present an adequate profile for conventional implantable medical devices.
[0027] The nonhermetic battery may provide advantages beyond the reduced profile of IMD 10. For example, compared to a hermetic battery, the nonhermetic battery expands the material and form factor choices available for the power source module housing. Increased packaging efficiency and the ability to select less expensive materials allows the nonhermetic battery to significantly reduce the cost of manufacturing IMD 10. In addition, the nonhermetic battery increases longevity and energy density per cubic centimeter. [0028] In general, a nonhermetic battery is built to perform substantially similar to a hermetic battery. For example, a nonhermetic battery may initially perform just as well in a helium leak test as a hermetic battery. However, unlike hermetic batteries which have enclosures that include welded, glassed, or braised seals, nonhermetic batteries typically have enclosures that include crimped seals. Over time, the crimped seals have a tendency to break down and leak substances, such as vaporized organic solvents, gasses produced during operation of the battery, and liquid electrolytes including salts.
[0029] The substances that may leak from the nonhermetic battery may contain corrosive compounds hamiful to IMD 10 and patient 14. IMD 10 includes a barrier to substantially impede the movement of substances from the nonhermetic battery to components in IMD 10. The barrier ensures that the substances from the nonhermetic battery will not harm patient 14 in which IMD 10 is implanted and will not damage the components. In some embodiments, the components comprise control electronics that control the functioning of the IMD. Several embodiments of the barrier will be described in greater detail below.
[0030] The nonhermetic battery can be applied within an IMD of any structure. For purposes of illustration, however, the invention will be described herein as a modular IMD housed in a member that at least partially encapsulates one or more housings of the modules and, and generally serves to provide a smooth interface between the modules and the body tissue. As will be described in greater detail below, IMD 10 comprises a plurality of separately housed and flexibly interconnected modules. By distributing components of IMD 10 among modules rather than including them within a single, rigid housing, the IMD may be shaped and configured for implantation at locations within patient 14 for which implantation of conventional IMDs is deemed undesirable or inapplicable. Further, the flexibility of the interconnection between modules of IMD 10 may allow multiples degrees of freedom of movement between the modules, which in turn may allow the implantable medical device to conform to such areas, and in particular embodiments, to conform to surfaces within patient 14 such as the surface of cranium 12. [0031] In the illustrated example, modular IMD 10 is coupled to two leads 16A and 16B (collectively "leads 16") that extend through holes within cranium 12, and into the brain of patient 14. In exemplary embodiments, each of leads 16 carries a plurality of electrodes, and IMD 10 delivers stimulation to the brain of patient 14 via the electrodes. Modular IMD 10 may be coupled to any number of leads 16, and in some embodiments is not coupled to any leads 16. In some embodiments, for example, IMD 10 may carry integrated electrodes.
[0032] Because modular IMD 10 can be implanted on cranium 12 of patient 14 rather then more remotely from the brain of patient 14, such as within a subclavicular region of patient 14, the problems associated with the use of long leads needed to allow a remotely implanted IMD to access the brain may be diminished or avoided. These problems include the requirement of tunneling under the scalp and the skin of the neck, increased surgery and recovery time, an additional procedure under general anesthesia, risk of infection or skin erosion along the track through which the leads are tunneled, and risk of lead fracture due to torsional and other forces caused by normal head and neck movements. [0033] FIG. 2 is a top- view diagram further illustrating IMD 10 implanted on cranium 12 of the patient 14. In order to implant modular IMD 10 on cranium 12, an incision 20 is made through the scalp of patient 14, and a resulting flap of skin is pulled back to expose the desired area of cranium 12. The incision may, as shown in FIG. 2, be generally shaped like a "C." Such an incision is commonly referred to as a "C-flap" incision.
[0034] Holes 22A and 22B (collectively "holes 22") are drilled through cranium 12, and leads 16 are inserted through holes 22 and into the brain of patient 14. Caps such as burr hole caps may be placed over holes 22 as is known in the art. Leads 16 are connected to modular IMD 10, either directly or via a lead extension, and modular IMD 10 is placed at least partially within a pocket formed using a hand or a tool beneath the scalp behind holes 22.
[0035] Once positioned as desired on cranium 12 within the pocket, modular IMD 10 may then be fixed to cranium 12 using an attachment mechanism such as bone screws. The skin flap may be closed over modular IMD 10, and the incision may be stapled or sutured. The location on cranium 12 at which IMD 10 is illustrated as implanted in FIG. 2 is merely exemplary, and IMD 10 can be implanted anywhere on the surface of cranium 12.
[0036] Because of the flexibility that may be provided by interconnect members of IMD 10 and/or a member of IMD 10 that at least partially encapsulates the modules of IMD 10 and provides a smooth interface between the modules and body tissue, the IMD may be manipulated during implantation such that it conforms to cranium 12. For example, in some embodiments a surgeon can manipulate modular IMD 10 into conformance with cranium 12 while IMD 10 is on cranium 12 and fix modular IMD 10 into place using bone screws or the like. In other embodiments, the clinician may manipulate modular IMD 10 into conformance with cranium 12 with IMD 10 on and/or off of cranium 12, and IMD 10 may substantially retain the form into which it is manipulated. [0037] As mentioned above, modular IMD 10 may deliver stimulation to the brain of patient 14 to, for example, provide deep brain stimulation (DBS) therapy, or to stimulate the cortex of the brain. Cortical stimulation may involve stimulation of the motor cortex. Modular IMD 10 may be used to treat any nervous system disorder including, but not limited to, epilepsy, pain, psychological disorders including mood and anxiety disorders, movement disorders (MND), such as, but not limited to, essential tremor, Parkinson's disease, and neurodegenerative disorders.
[0038] However, modular IMD 10 is not limited to delivery of stimulation to the brain of patient, and may be employed with leads 16 deployed anywhere in the head or neck including, for example, leads deployed on or near the surface of the skull, leads deployed beneath the skull such as near or on the dura mater, leads placed adjacent cranial or other nerves in the neck or head, or leads placed directly on the surface of the brain. Moreover, modular IMD 10 is not limited to implantation on cranium 12. Indeed, modular IMD 10 may be implanted anywhere within patient 14. For example, modular IMD 10 can be implanted within the neck of patient 14, and deliver stimulation to the vagus nerve or the cervical region of the spinal cord.
[0039] Modular IMD 10 may alternatively be implanted within a pectoral region or the abdomen of patient 14 to act as a diaphragmatic pacer, or to provide any of the monitoring and therapy delivery functions known in the art to be associated with cardiac pacemakers. Further, modular IMD 10 may be implanted in the upper buttock region and deliver spinal cord, urological or gastrological stimulation therapy, or may be configured to be implanted within the periphery, e.g., limbs, of patient 14 for delivery of stimulation to the muscles and/or peripheral nervous system of patient 14. Additional implant locations may include the abdomen, e.g., for gastric stimulation. As is the case with cranium 12, the modularity of IMD 10 may enable implantation at some of these example locations for which implantation of conventional IMDs is generally deemed undesirable. [0040] Modular IMD 10 is not limited to embodiments that deliver stimulation. For example, in some embodiments modular IMD 10 may additionally or alternatively monitor one or more physiological parameters and/or the activity of patient 14, and may include sensors for these purposes. Where a therapy is delivered, modular IMD 10 may operate in an open loop mode (also referred to as non-responsive operation), or in a closed loop mode (also referred to as responsive). Modular IMD 10 may also provide warnings based on the monitoring.
[0041] As discussed above, the ability of a modular IMD 10 according to the invention to be implanted close to a region within patient 14 to be monitored enables the use of shorter leads 16. Shorter leads 16 may advantageously improve the accuracy of such sensors by reducing noise attributable to leads 16. Shorter leads 16 may also advantageously reduce the negative affects of imaging techniques such as magnetic resonance imaging "MRI" on a person implanted with IMD 10. Within an MRI machine, leads act as antennas positioned very close to an antenna tower, therefore using shorter leads 16 reduces an amount of energy induced onto IMD 10 from the MRI machine.
[0042] Further, in some embodiments modular IMD 10 can additionally or alternatively deliver a therapeutic agent to patient 14, such as a pharmaceutical, biological, or genetic agent. Modular IMD 10 may be coupled to a catheter, and may include a pump to deliver the therapeutic agent via the catheter. [0043] FIG. 3 is a top-view diagram further illustrating modular IMD 10. In the illustrated embodiment, modular IMD 10 includes three modules: a control module 30, a power source module 32, and a recharge module 34. As shown in FIG. 3, modules 30, 32 and 34 include separate housings 36, 38 and 40, respectively.
[0044] Control module 30 includes components within the housing. In some embodiments, the components comprise control electronics, e.g., electronics that control the monitoring and/or therapy delivery functions of modular IMD 10, such as a microprocessor. Control module 30 may also include circuits for telemetry communication with external programmers or other devices within the housing. Housing 36 of control module 30 may be hermetic in order to protect the components therein, and in exemplary embodiments is formed of a rigid material, such as titanium, stainless steel, or a ceramic. In exemplary embodiments, housing 36 is a low-profile, concave housing to substantially conform to a patient's cranium.
[0045] Power source module 32 includes a nonhermetic battery. A nonhermetic battery is a battery contained within a nonhermetic housing or other nonhermetic enclosure, e.g., a housing or enclosure, as described above. The nonhermetic battery is then further housed within housing 38. The nonhermetic battery provides power for components of other modules, such as the components within control module 30. The nonhermetic battery may be any nonhermetic battery suitable for use within an IMD. In an exemplary embodiment, the nonhermetic battery comprises a rechargeable Lithium Ion battery with a flexible foil pack construction to more easily fit within housing 38, which may be less than approximately 5 millimeters thick in a direction normal to a major plane of the housing. The major plane of housing 38 may include an approximately one square inch (6.5 square centimeters) surface area. Housing 38 may be hermetic, and may be formed of titanium, stainless steel, or a ceramic. Power source module 32 may include an insulator within housing 38 to electrically isolate housing 38 from the nonhermetic battery.
[0046] Including the nonhermetic battery in power source module 32 reduces a thickness and overall size of housing 38, which may then reduce a profile of IMD 10. The low profile of IMD 10 permits IMD 10 to be deployed effectively, comfortably and cosmetically within patient 14. In one embodiment of the invention, IMD 10 including the nonhermetic battery has a maximum thickness of between approximately 1 millimeter and approximately 5 millimeters. The use of a reduced profile may reduce the risk of infection, skin erosion and cosmetic issues related to the implantation of IMD 10.
[0047] Where the nonhermetic battery comprises a rechargeable nonhermetic battery, modular IMD 10 may include recharge module 34. Recharge module 34 includes a recharge coil (not shown) within housing 40. The recharge coil inductively receives energy from an external recharging unit (not illustrated) through the skin of patient 14 to recharge the nonhermetic battery. The recharge coil may be formed of windings of copper or another highly conductive material. Housing 40 need not be heraietic, and may be formed of materials such as silicone, polymers and ceramics.
[0048] Housings 36, 38 and 40 may have any shape, including the round, coin shape and rectangular shapes with rounded edges illustrated in FIG. 3. Further, one or more surfaces of one or more of housings 36, 38 and 40 may be concave along at least one axis, and preferably two axes.
[0049] Modules 30, 32 and 34 can be configured in a variety of ways, and the configuration illustrated in FIG. 3 is merely exemplary. Further, modular IMD 10 can include any number of modules, and may include other types of modules instead of or in addition to a control module 30 and a recharge module 34. For example, modular IMD 10 can include a module within another module, such as power source module 32 within control module 30. In addition, modular IMD 10 can include additional power source modules, modules that include additional memory that is accessible by the components, modules that include reservoirs for storing therapeutic agents and pumps for delivering therapeutic agents to patient 14, and modules that include sensors sensing physiological parameters, such as pressures or blood flows, or the activity level of patient 14. [0050] Power source module 32 is coupled to control module 30 by a flexible interconnect member 44, which encloses an electrical conductor that allows transmission of energy from the nonhermetic battery of power source module 32 to components such as the components within control module 30. In embodiments where energy is transferred via a DC voltage on the electrical conductor, it may be necessary to make flexible interconnect member 44 hermetic. In embodiments in which flexible interconnect member 44 is hermetic, flexible interconnect member 44 may be made of titanium, stainless steel, or nitinol. In embodiments where energy is transferred via a charge-balance voltage on the electrical conductor, such as an AC voltage, flexible interconnect member 44 need not be hermetic, and may be made of any material including silicone or various polymers. [0051] In the illustrated embodiment, the components of control module 30 regulate the recharging and discharging of the nonhermetic battery within power source module 32. Consequently, as shown in FIG. 3, recharge module 34 is coupled to control module 30 by a flexible interconnect member 46 that encloses an electrical conductor that allows transmission of energy inductively received by the recharge coil within recharge module 34 to control module 30. Because the energy is transferred on the electrical conductor via a charge-balanced voltage, flexible interconnect member 46 need not be hermetic, and may be made of any material including titanium, stainless steel, nitinol, ceramics, silicone or various polymers.
[0052] Interconnect members 44 and 46 are flexible. In some embodiments, as indicated above, interconnect members 44 and 46 are made of a flexible material such as silicone, a flexible polymer, or nitinol. In embodiments where flexible member 44 is hermetic and made of a substantially less flexible material, such as titanium or stainless steel, the flexibility of interconnect member 44 is provided by the configuration and/or construction of flexible interconnect member 44. [0053] Interconnect member 44 is flexible in a plurality of directions to provide modules 30 and 32 with multiple degrees of freedom of motion with respect to each other. In exemplary embodiments, interconnect member 44 provides at least three degrees of motion, and the degrees of motion provided include rotational motion.
[0054] As shown in FIG. 3, modular IMD 10 includes a member 48, which may be flexible and made of a soft biocompatible material. Member 48 at least partially encapsulates one or more of housings 36, 38 and 40, and generally serves to provide a smooth interface between the modules and the body tissue. Member 48 may integrate modules 30, 32 and 34 into a desired form factor, but, where flexible, allow relative intermodule motion. In some embodiments, member 48 incorporates mechanical features to restrict intermodule motion to certain directions or within certain ranges. Member 48 may be made from silicone, and in some embodiments may be made from two or more materials of differing flexibility, such as silicone and a polyurethane. An exemplary polyurethane for this purpose is Tecothane®, which is commercially available from Hermedics Polymer Products, Wilmington, MA. Member 36 may also be referred to as an "overmold," but use of the term "overmold" herein is not intended to limit the invention to embodiments in which member 36 is a molded structure. Member 36 may be a molded structure, or may be a structure formed by any process. [0055] Member 48 can be shaped to contour to cranium 12, e.g., may be concave along at least one axis, and may be contoured at its edges to prevent skin erosion on the scalp of patient 14. The flexibility and shape of member 48 may, in some embodiments, improve the comfort and cosmetic appearance of modular IMD 10 under the scalp, and may make IMD 10 more clinically acceptable by, for example, reducing the likelihood of skin erosion.
[0056] In the illustrated embodiment, modular IMD 10 also includes lead connector modules 50A and 50B (collectively "lead connector modules 50") formed within member 48 to receive leads 16 or lead extensions coupled to leads 16. Conductors 52 extend from lead connector modules 50 to hermetic feedthroughs (not illustrated) within housing 36 of control module 30. Lead connector modules 50 may be formed anywhere within member 48. In embodiments where member 48 includes a rigid material in addition to a flexible material, the rigid material may form at least part of lead connector modules 50 to secure leads 16 or lead extensions, and to protect conductors 52 from damage that may result from flexing within member 48.
[0057] FIG. 4 is a block diagram illustrating control module 30 of modular IMD 10. As described above, control module 30 includes components, such as control electronics that control the functioning of modular IMD 10 within housing 36. The components include a processor 60, which may take the form of a microprocessor, digital signal processor (DSP), application specific integrated circuit (ASIC), field- programmable gate array (FPGA), or other logic circuitry. [0058] Control module 30 also includes a memory 62, such as a read-only memory (ROM), random access memory (RAM), electronically-erasable programmable ROM (EEPROM), flash memory, or the like. Memory 62 may store program instructions that may be executed by processor 60 and thereby control the functioning of modular IMD 10. Processor 60 may also store data colleted during treatment and/or monitoring of patient 14 within memory 62. [0059] In some embodiments, control module 30 includes telemetry circuitry 64, which enables processor 60 to communicate with other devices such as an external programming device via radio-frequency communication. Telemetry circuitry 64 may include a telemetry coil (not illustrated), which may be fabricated of windings of copper or another highly conductive material. The configuration and location of the telemetry coil within housing 36 may be dictated by the available space within housing 36 and the communication requirements of telemetry circuitry 64. [0060] In some embodiments, modular IMD 10 delivers electrical stimulation, and more particularly, control module 30 includes therapy delivery circuitry 66 within housing 36 that generates electrical stimulation. In exemplary embodiments, therapy delivery circuitry 66 comprises circuits for the generation of electrical stimulation in the form of pulses, such as capacitors and switches. In embodiments in which modular IMD 10 is a neurostimulator coupled to leads 16 that include a plurality of electrodes, therapy delivery circuitry 66 may deliver the pulses to a switch matrix 68, which comprises an array of switches. In such embodiments, processor 60 interacts with switch matrix 68 to select electrodes for delivery of generated stimulation pulses. Based on the selections made by processor 60, switch matrix 68 delivers the pulses to conductors that pass through feedthroughs in housing 36 and to electrical contacts on leads 16 that are electrically coupled to the desired electrodes carried by leads 16.
[0061] The illustrated components of control module 30 receive energy from the nonhermetic battery within power source module 32 via interconnect member 44 (FIG. 3). In some embodiments in which the nonhermetic battery is rechargeable, control module 30 receives energy inductively captured by recharge module 34 via interconnect member 46, and includes power management circuitry 70 that controls the recharging and discharging of the nonhermetic battery. Power management circuitry 70 may ensure that the nonhermetic battery is not overcharged, over-discharged, or harmed. In some embodiments, power management circuitry 70 includes circuits to measure voltages, currents or temperatures associated with the nonhermetic battery, or rates of change of these parameters, and controls recharging and discharging according to the measured values. Power management circuitry 70 may also include circuits, such as rectifier circuits, for converting charge-balanced voltages, e.g., AC voltages, provided by a recharge coil (not shown) into net DC voltages for recharging the nonhermetic battery.
[0062] FIG. 5 is a block diagram illustrating power source module 32 of modular IMD 10. Power source module 32 includes a rechargeable nonhermetic battery 72 within housing 38. In the illustrated embodiment in which power source module 32 directly receives energy inductively captured by recharge module 34 via flexible interconnect member 44, power source module 32 also includes power management circuit 74 that controls the recharging and discharging of nonhermetic battery 72. As described above with reference to power management circuitry 70 of control module 30 illustrated in FIG. 4, power management circuitry 74 may ensure that nonhermetic battery 72 is not overcharged, over-discharged, or harmed. In some embodiments, power management circuitry 74 includes circuits to measure voltages, currents or temperatures associated with nonhermetic battery 72, or rates of change of these parameters, and controls recharging and discharging of nonhermetic battery 72 according to the measured values.
[0063] Power management circuitry 74 may also include circuits, such as rectifier circuits, for converting charge-balanced voltages, e.g., AC voltages, provided by a recharge coil (not shown) into DC voltages for recharging nonhermetic battery 72. In some embodiments in which interconnect member 44 is nonhermetic, power management circuitry 74 includes modulating circuits, i.e., circuits that enable power management circuit 74 to deliver energy to control module 30 in the form of charge-balanced voltages on an electrical conductor. In such embodiments, control module 30 includes circuits, such as rectifier circuits, to convert the charge- balanced voltages to DC voltages for use by components of control module 30. [0064] FIGS. 6-11 are block diagrams illustrating example IMDs including barriers, in accordance with embodiments of the invention, that substantially impede movement of substances from a nonhermetic battery to components within the example IMDs. In some embodiments, the components comprise control electronics. The substances from the nonhermetic battery may contain corrosive compounds, such as vaporized organic solvents, gasses produced during operation of the battery, and liquid electrolytes including salts. The barriers impede the movement of substances from the nonhermetic battery to the components so that the corrosive compounds cannot cause damage. The damage would not only be harmful to the IMD, but could potentially be harmful to a patient in whom the IMD is implanted. For example, the substances from the nonhermetic battery that contain corrosive compounds may enter the patient's body. In addition, the damaged IMD may malfunction, e.g., abruptly quit delivering therapy or deliver inappropriate therapy to the patient.
[0065] The example IMDs may operate substantially similar to IMD 10 described above. Each of the barriers may be used individually or in combination with one another. For purposes of illustration, each of the IMDs illustrated in FIGS. 6-11 comprises one electrical conductor between the nonhermetic battery and the components. Typically, at least two electrical conductors are included to allow electrical isolation between a housing of the nonhermetic battery and a case of the IMD. In that way, the case of the IMD may be used as an electrical element for interaction with an electrode, for example. Again, the invention may be included in an IMD of any structure, but will be described herein as embodied within a modular IMD.
[0066] FIGS. 6A and 6B are block diagrams illustrating a top view and a side view, respectively, of an example IMD 78. IMD 78 includes a power source module 80 that includes a power source module housing 81 and a nonhermetic battery 84 within power source module housing 81. Additionally, IMD 78 further includes a control module 82 that includes a control module housing 83 and components 86 within control module housing 83. An electrical conductor 88 extends from nonhermetic battery 84 to components 86 and delivers power from nonhermetic battery 84 to components 86. Power source module 80 and control module 82 are coupled via an interconnect member 90, through which conductor 88 extends.
[0067] IMD 78 comprises a hermetic feedthrough 92 that acts as a barrier to substantially impede movement of substances, such as vaporized organic solvents, gasses produced during operation of the battery, and liquid electrolytes including salts, from nonhermetic battery 84 to components 86. Electrical conductor 88 extends through hermetic feedthrough 92 between nonhermetic battery 84 and components 86. As shown in FIGS. 6A and 6B, hermetic feedthrough 92 is positioned at an interface area 93 where power source module 80 and interconnect member 90 couple to each other. In that way, hermetic feedthrough 92 may ensure that no corrosive compounds included in the substances from nonhermetic battery 84 can leave power source module housing 81. As opposed to a nonhermetic feedthrough comprising a rivet that, over time, may allow the substances to leak, a hermetic feedthrough comprises a weld or a braise that maintains a substantially permanent air-tight seal.
[0068] As hermetic feedthrough 92 blocks the movement of substances from reaching components 86, at least a portion of hermetic feedthrough 92 is exposed to the corrosive compounds within the substances. The exposed portion of hermetic feedthrough 92 may be subject to corrosive effects, especially at contact points with power source module housing 81 and nonhermetic battery 84. Therefore, in order to connect hermetic feedthrough 92 to the positive pole of nonhermetic battery 84, a selected pin material must be able to avoid corrosion. For example, a Niobium pin may be prone to corrosion, but suitable corrosion- resistant pin materials may include Ti-6V-4A1, aluminum, or molybdenum. In addition, hermetic feedthrough 92 may comprise a suitable corrosion-resistant feedthrough glass material, such as Cabal- 12.
[0069] In the illustrated embodiment, only one hermetic feedthrough 92 is used. Therefore, interconnect module 90 is a conductor in electrical contact with one of the poles of nonhermetic battery 84. In other embodiments, additional hermetic feedthroughs may be included in IMD 78. For example, if two hermetic feedthroughs are used, interconnect member 90 can be electrically insulated from nonhermetic battery 84. Additional feedthroughs may also be used to connect control module 82 to sensors in power source module 80. The sensors may detect temperature or, in the case of a voltage reference electrode, battery status. [0070] Hermetic feedthrough 92 forms apart of power source module housing 81. However, hermetic feedthrough 92 in power source module housing 81 causes interface area 93 and interconnect member 90 to comprise thicknesses at least as thick as an outside cross-sectional area of hermetic feedthrough 92. As shown in FIG. 6B, power source module housing 81 remains thin until interface area 93. The illustrated embodiment allows IMD 78 to have a maximum thickness of between approximately 3 millimeters and approximately 8 millimeters. [0071] FIGS. 7A and 7B are block diagrams illustrating a top view and a side view, respectively, of another example IMD 94. IMD 94 includes a power source module 96 that includes a power source module housing 97 and a nonhermetic battery 100 within power source module housing 97. Additionally, IMD 94 further includes a control module 98 that includes a control module housing 99 and components 102 within control module housing 99. An electrical conductor 104 extends from nonhermetic battery 100 to components 102 and delivers power from nonhermetic battery 100 to components 102. Power source module 96 and control module 98 are coupled via an interconnect member 106, through which conductor 104 extends.
[0072] IMD 94 comprises a hermetic feedthrough 108 that acts as a barrier to substantially impede movement of substances from nonhermetic battery 100 to components 102. Electrical conductor 104 extends through hermetic feedthrough 108 between nonhermetic battery 100 and components 102. As shown in FIGS. 7 A and 7B, hermetic feedthrough 108 is positioned at an interface area 109 where interconnect member 106 and control module 98 couple to each other. In that way, hermetic feedthrough 108 may ensure that no corrosive compounds included in the substances from nonhermetic battery 100 can enter control module housing 99. Hermetic feedthrough 108 may be substantially similar to hermetic feedthrough 92 described in reference to FIGS. 6 A and 6B.
[0073] Hermetic feedthrough 108 forms a part of control module housing 99. However, hermetic feedthrough 108 in control module housing 99 causes interface area 109 of interconnect member 106 to comprise a thickness at least as thick as an outside cross-sectional area of hermetic feedthrough 92. As shown in FIG. 7B, power source module housing 97 and interconnect member 106, until interface area 109, comprise thicknesses less than an outside area of hermetic feedthrough 108. The illustrated embodiment allows IMD 94 to have a maximum thickness of between approximately 3 millimeters and approximately 8 millimeters [0074] In addition to the positions of hermetic feedthroughs 92 and 108 described above, a hermetic feedthrough may be located at any position along an interconnect member, such as interconnect member 106. The interconnect member may be constructed in two sections joined together by, for example, welding. Movement of substances from a nonhermetic battery may subject the welded areas of the interconnect member to corrosive effects. The hermetic feedthrough may be positioned between the two sections to block the movement of substances from . damaging the welded areas of the interconnect member and components within the IMD.
[0075] FIG. 8 is a block diagram illustrating a top view of an example IMD 110. IMD 110 includes a power source module 112 that includes a power source module housing 113 and a nonhermetic battery 116 within power source module housing 113. Additionally, IMD 110 further includes a control module 114 that includes a control module housing 115 and components 118 within control module housing 115. An electrical conductor 120 extends from nonhermetic battery 116 to components 118 and delivers power from nonhermetic battery 116 to components 118. Power source module 112 and control module 114 are coupled via an interconnect member 122, through which conductor 120 extends. [0076] IMD 110 comprises a first seal member 124 and a second seal member 126 that act as barriers to substantially impede movement of substances from nonhermetic battery 116 to components 118. First seal member 124 is positioned within interconnect member 122 where interconnect member 122 couples to power source module 112. First seal member 124 blocks the movement of substances from leaving the power source module housing 113. Second seal member 126 is positioned within interconnect member 122 where interconnect member 122 couples to control module 114. Second seal member 126 blocks the movement of substances from entering the control module housing 115. In embodiments where interconnect member 122 comprises a cylindrical shape, first and second seals 124, 126 may comprise o-ring, gasket, or grommet seals. In some embodiments, only one of the first and second seal members is included within IMD 110. In other embodiments, a plurality of seal members may be positioned at a plurality of locations within IMD 110.
[0077] First and second seals 124, 126 may comprise materials with low permeability and high creep resistance. For example, these materials may be cross-linked crystalline materials that are either rigid or elastomeric. A partial list of rigid materials includes polypropylene, high density polyethylene, polyester, and engineering plastics such as polymers containing ether ketones (PEK, PEEK), polyether imide (PEI), polyamide imide (PAI), polyphenylene oxide (PPO), polyether sulfone (PES), and polyphenylene sulfide (PPS). A partial list of elastomers includes EPDM (ethylene-propylene-diene terpolymer), isoprene, polyurethanes, silicones, and thermoplastic elastomers (TPE) such as styrenic block copolymers (SBC), thermoplastic olefins (TPO), and copolyesters (COPE). Examples of TPE trade names include Kraton®, Dynaflex®, Nersaflex®, Nersalloy® and Nersollan from Dynaflex Corp., Grand Rapids, MI. [0078] FIG. 9 is a block diagram illustrating a top view of an example IMD 128. IMD 128 includes a power source module 130 that includes a power source module housing 131 and a nonhermetic battery 134 within power source module housing 131. Additionally, IMD 128 further includes a control module 132 that includes a control module housing 133 and components 136 within control module housing 133. An electrical conductor 138 extends from nonhermetic battery 134 to components 136 and delivers power from nonhermetic battery 134 to components 136. Power source module 130 and control module 132 are coupled via an interconnect member 140, through which conductor 138 extends. Interconnect member 140 may define a void through which electrical conductor 138 extends. [0079] The void of interconnect member 140 is filled with a material 141 to substantially impede movement of substances from nonhermetic battery 134 to components 136. In some embodiments, the interconnect member void is only partially filled with material 141. Material 141 may be one of backfilled, flowed, and inserted into the void of interconnect member 140. In the case where material 141 is inserted into the void, material 141 may be manipulated after insertion to create a substantially permanent air-tight seal with interconnect member 141. Material 141 is substantially impermeable to the substances from nonhermetic battery 134. Therefore, material 141 blocks corrosive compounds within the substances from reaching components 136 and potentially damaging IMD 128 and injuring a patient in which IMD 128 is implanted. Material 141 may also be flexible to allow interconnect member 140 to bend and flex, as described above. [0080] A suitable material 141 may include a thermoplastic polymer such as polyolefin or ethylvinyl acetate. Material 141 may also comprise a thermosetting resin introduced to interconnect member 140 in a liquid or molten state and cured after filling. Examples of thermosetting resins include epoxies, silicones, polyurethanes, and isocyanates. It is advantageous to have material 141 comprise a material that expands, or at least minimally contracts, upon solidification. In that case, another example of material 141 may comprise a closed-cell foam that forms a gas upon curing such as isocyanate-terminated polyurethanes and acrylic latex polymers. Isocyanates, which have the property of forming strong bonds to metals such as aluminum, are therefore useful for forming a tight, permanent seal within interconnect member 140.
[0081] Material 141 may also include fillers that may be in a finely divided form such as flakes or powders. Fillers may either impart low permeability or absorption of the substances from nonhermetic battery 134. Absorbents may include getters described in more detail below. Materials with low permeability may include minerals, e.g., mica, ceramics, metals, and polymers. Material 141 may comprise a nonconductive metal, such as aluminum. If material 141 includes metals that would render material 141 electrically conductive, then nonhermetic battery 134 may require a complete or partial layer of electrical insulation from material 141. The electrical insulation may be a paint, a conformal coating, a potting compound, a polymer film, a ceramic, an oxide, or a passivation layer. [0082] FIG. 10 is a block diagram illustrating a top view of an example IMD 142. IMD 142 includes a power source module 144 that includes a power source module housing 145 and a nonhermetic battery 148 within power source module housing 145. Additionally, IMD 142 further includes a control module 146 that includes a control module housing 147 and components 150 within control module housing 147. An electrical conductor 152 extends from nonhermetic battery 148 to components 150 and delivers power from nonhermetic battery 148 to components 150. Power source module 144 and control module 146 are coupled via an interconnect member 154, through which conductor 152 extends. [0083] Power source control module 144 includes a material 156 that substantially encapsulates nonhermetic battery 148 within power source module housing 145. In some embodiments, material 156 may only partially encapsulate nonhermetic battery 148. Encapsulating nonhermetic battery 148 within material 156 substantially blocks movement of substances from leaving power source module housing 145. Material 156 is impermeable by corrosive compounds included in the substances from nonhermetic battery 148. The substances typically move out of nonhermetic battery 148 along termination wires or joints between sections of a battery case (not shown) or between the battery case and a nonhermetic feedthrough. Specifically designing material 156 to be resistant to the movement of substances from nonhermetic battery 148 at those locations increases containment of the corrosive compounds that may harm components 150 and a patient in which IMD 142 is implanted.
[0084] In some embodiments, nonhermetic battery 148 may be polymerized in place within power source module housing 145 with material 156. In that case, material 156 may comprise a thermosetting plastic, such as silicone, epoxy, or polyester. In other embodiments, material 145 may comprise a thermoplastic that, when melted, flows into power source module housing 145 to surround nonhermetic battery 148. In that case, material 145 may comprise a polyolefin, which includes polyethylene and polypropylene. In addition, material 145 may comprise one of the materials listed above for seal members 124 and 126 (FIG. 8) and material l41 (FIG. 9).
[0085] FIG. 11 is a block diagram illustrating a top view of an example IMD 158. IMD 158 includes a power source module 160 that includes a power source module housing 161 and a nonhermetic battery 164 within power source module housing 161. Additionally, IMD 158 further includes a control module 162 that includes a control module housing 163 and components 166 within confrol module housing 163. An electrical conductor 168 extends from nonhermetic battery 164 to components 166 and delivers power from nonhermetic battery 164 to components 166. Power source module 160 and control module 162 are coupled via an interconnect member 170, through which conductor 168 extends. [0086] The movement of substances may be impeded by a length and/or cross- sectional area of interconnect member 170. A long interconnect member allows the substances from nonhermetic battery 164 to dissipate before reaching components 166. A small interconnect member cross-sectional area increases resistance against the movement to slow the diffusion rate of the substances from nonhermetic battery 164 to components 166. The ratio of interconnect member length to internal area should be kept as large as possible to increase diffusional resistance. In an embodiment where interconnect member 170 comprises a cylindrical shape, the ratio of interconnect member length to outside diameter is at least 10. As an example, an interconnect member length of 3 inches and an outside diameter of 0.05 inch gives a ratio of 60. The interconnect member ratio may also be applied to any of the IMDs described above.
[0087] As shown in FIG. 11, interconnect member 170 is crimped to create reduced-area regions 172 that substantially impede movement of substances from nonhermetic battery 164 to components 166. Crimping interconnect member 170 may involve pinching, rolling, drawing, or a combination thereof. In other embodiments, a plurality of reduced-area regions may be created along the length of interconnect member 170.
[0088] In some embodiments, a void defined by interconnect member 170 is at least partially filled with a material, substantially similar to FIG. 9. Reduced- cross-sectional area regions 172 are created after placing the material within the void of interconnect member 170. The material creates a pressure seal within interconnect member 170 at each reduced-cross-sectional area region 172. Refer to FIGS. 8 and 9 for a listing of materials that are only minimally permeable by substances from nonhermetic battery 164, and resistant to creep. [0089] IMD 158 may also include a getter to substantially impede the movement of substances from nonhermetic battery 164 to components 166. The getter may be located within at least one of power source module 160, interconnect member 170, and confrol module 162. The getter absorbs or reacts with the substances within IMD 158 to form a solid nonvaporizable material or to substantially eliminate the corrosive compounds and/or elements that create corrosive compounds included in the substances from nonhermetic battery 164. In some embodiments, several getters are included in IMD 158. The getter may also be included within any of the IMDs described above.
[0090] The getter may comprise a desiccant, or any other type of getter for water. Common types of desiccants are silica gel or calcium carbonate, silico-aluminate, clay (montmorillonite), and molecular sieve. If PF6 leaks out of nonhermetic battery 164 and water is available, the compounds will react to produce hydrofluoric acid (HF). However, if no water is available, no HF can be created. If any HF were to come in contact with components 166, it would damage components 166 and potentially injure a patient in which IMD 158 is implanted. [0091] The getter may also comprise a getter for HF, such as fumed or gelled silica because silica is an excellent HF getter. The getter may further comprise a getter for organics. For example, the organic getter may be a type of carbon such as activated charcoal. Carbon has the ability to be formed and pressed into a specific shape, which allows the organic getter to fit in a variety of positions within IMD 158.
[0092] The getter may be located anywhere within the volume of IMD 158. Further, the getter may be randomly placed in IMD 158 between nonhermetic battery 164 and components 166. The getter may also be directly incorporated within a material to form elements such as seal members, material to fill interconnect member 170, material to encapsulate nonhermetic battery 164, or the like. For example, Multisorb Incorporated of Buffalo, NY, USA manufactures desiccants in forms that may incorporate easily within IMD 158, including machinable material, hot-melt glue, and plastic films.
[0093] In addition, nonhermetic battery 164 may include a gel, polymer, or solid electrolyte instead of a gas or liquid electrolyte. The gel, polymer, or solid electrolyte acts as a barrier within nonhermetic battery 164 by substantially eliminating movement of substances from nonhermetic battery 164. The gel, polymer, or solid electrolyte reduces vapor pressure within nonhermetic battery 164, which reduces a chance of nonhermetic battery 164 leaking. Furthermore, if nonhermetic battery 164 does leak, the gel, polymer, or solid electrolyte has a much smaller chance of leaving nonhermetic battery 164 than a gas or fluid electrolyte. An electrolyte gelling agent such as polyvinylidene fluoride (PNDF), polyvinylidene fluoride-hexafluoropropylene (PNDF-HFP) copolymer, polyethylene oxide (PEO), silicon, or a mixture thereof, is used to create the gelled electrolyte. The polymer or solid electrolyte may create a thin- film nonhermetic battery. The solid electrolyte may comprise ceramic or glass. The nonhermetic batteries included in the IMDs described above may also include the gel, polymer, or solid electrolyte.
[0094] In some embodiments, IMD 158 may not include power source module housing 160. In that case, nonhermetic battery 164 may couple directly to interconnect member 170 by a hermetic weld or braise around the connection area. Sealing the interface area between nonhermetic battery 164 and interconnect member 170 substantially blocks the substances from entering the patient's body. Eliminating the power source module housing 160 allows IMD 158 to comprise a further reduced profile thickness. The IMDs described above may also not include a power source module housing that fully encapsulates the nonhermetic battery. [0095] FIG. 12 is a block diagram illustrating a top view of another example IMD 174. IMD 174 includes a power source module 176 that includes a power source module housing 177 and a nonhermetic battery 180 within power source module housing 177. Control module 178 includes a control module housing 179 and components 182 within control module housing 179. Power source module 176 is included within control module housing 179. An electrical conductor 184 extends from nonhermetic battery 180 to components 182 and delivers power from nonhermetic battery 180 to components 178. In some embodiments, components 182 may comprise control electronics.
[0096] IMD 174 illustrates an IMD set-up as an alternative to the IMDs illusfrated in FIGS. 6-11. The illustrated embodiment may correspond to a non-modular IMD. For example, IMD 174 may comprise a conventional IMD with a single housing that houses substantially all of the IMD's components. The barriers described above may also be applied to IMD 174 to block, absorb and/or dissipate the movement of substances between nonhermetic battery 180 and components 182.
[0097] Various embodiments of the invention have been described. For example, an implantable medical device (IMD) including a nonhermetic battery has been described. The nonhermetic battery reduces a profile and a manufacturing cost of the IMD. The IMD also includes a barrier to impede movement of substances from the nonhermetic battery from reaching components within the IMD and injuring a patient in which the IMD is implanted. A variety of barriers are described including hermetic feedthroughs, seal members, material to encapsulate the nonhermetic battery, chemical getters, and gel, polymer, or solid electrolytes. A modular IMD is also described that includes an interconnect member to couple a module including the nonhermetic battery to a module including the components. Barriers may also be including in the interconnect member, such as length, cross- sectional area, and material filling at least a portion of a void defined by the interconnect member.
[0100] Nevertheless, various modifications may be made to the described embodiments. For example, the IMD described above may include any nonhermetic electro-chemical generator, such as a fuel cell, instead of a nonhermetic battery. A fuel cell is designed to vent the substances created by operation. The barriers provided by the invention enable a fuel cell or similar generator to be included in an IMD as the barriers substantially impede the movement of substances. Furthermore, the components with the IMD may refer to control electronics as well as sensor control components and other control mechanisms that may or may not be included within the control module housing.

Claims

CLAIMS:
1. An implantable medical device comprising: components; a power source module that includes a nonhermetic battery; an electrical conductor that delivers power from the nonhermetic battery to the components; and a barrier between the components and the nonhermetic battery that substantially impedes movement of substances from the nonhermetic battery to the components.
2. The implantable medical device of claim 1, wherein the barrier comprises a hermetic feedthrough and the electrical conductor extends through the feedthrough.
3. The implantable medical device of claim 2, further comprising a power source module housing, wherein the nonhermetic battery is located within the power source module housing and the hermetic feedthrough forms a part of the power source module housing.
4. The implantable medical device of claim 2, further comprising a control module including a control module housing, wherein the components are located within the control module housing and the hermetic feedthrough forms a part of the confrol module housing.
5. The implantable medical device of claim 1 , wherein the barrier comprises a seal member.
6. The implantable medical device of claim 5, further comprising: a confrol module including a control module housing, wherein the components are located within the control module housing; and an interconnect member to couple the control module and the power source module, wherein the conductor extends through the interconnect member, wherein the seal member is positioned within the interconnect member one of where the interconnect member is coupled to the control module and where the interconnect member is coupled to the power source module.
7. The implantable medical device of claim 5, wherein the seal member comprises one of an o-ring, a gasket, or a grommet seal.
8. The implantable medical device of claim 1, further comprising: a control module including a confrol module housing, wherein the components are located within the confrol module housing; and an interconnect member to couple the control module and the power source module, wherein the interconnect member defines a void and the conductor extends through the interconnect member void, wherein the barrier comprises a material that fills at least a portion of the interconnect member void and is substantially impermeable by the substances from the nonhermetic battery.
9. The implantable medical device of claim 8, wherein the material comprises at least one of a polymer, a resin, a filler, or a finely divided filler.
10. The implantable medical device of claim 8 or 9, wherein the material substantially absorbs the substances from the nonhermetic battery.
11. The implantable medical device of any one of claims 8 to 10, wherein the interconnect member is crimped at a location where the material fills the interconnect member void to create a reduced-cross-sectional area region.
12. The implantable medical device of claim 1, wherein the barrier comprises a material that encapsulates at least a portion of the nonhermetic battery and is substantially impermeable by the substances from the nonhermetic battery.
13. The implantable medical device of claim 12, wherein the material comprises one of a polymer and a resin.
14. The implantable medical device of claim 1, wherein the barrier comprises a getter that one of substantially absorbs or reacts with the substances from the nonhermetic battery.
15. The implantable medical device of claim 14, wherein the getter comprises one of a water getter, a salt getter, a hydrofluoric acid getter, or an organic getter.
16. The implantable medical device of claim 14 or 15, further comprising: a power source module housing, wherein the nonhermetic battery is located within the power source module housing; a control module including a confrol module housing, wherein the components are located within the control module housing; and an interconnect member to couple the control module and the power source module, wherein the conductor extends through the interconnect member, wherein the getter is located within at least one of the power source module housing, the interconnect member, or the confrol module housing.
17. The implantable medical device of claim 1 , wherein the barrier comprises one of a gel, a polymer, or a solid electrolyte within the nonhermetic battery that substantially eliminates the movement of substances from the nonhermetic battery.
18. The implantable medical device of claim 1 , further comprising: a control module including a control module housing, wherein the components are located within the confrol module housing; and an interconnect member to couple the confrol module and the power source module, wherein the conductor extends through the interconnect member, wherein the barrier comprises at least one of a length of the interconnect member that dissipates movement of substances from the nonhermetic battery to the components or a cross-sectional area of the interconnect member that substantially impedes movement of substances from the nonhermetic battery to the components.
19. The implantable medical device of claim 18, wherein the interconnect member is crimped to create a reduced-area region.
20. The implantable medical device of claim 1, wherein the components comprise control electronics.
21. A method of manufacturing an implantable medical device, the method comprising: forming a control module including components; forming a control module housing to house the components; forming a power source module including a nonhermetic battery; forming a power source module housing to house the nonhermetic battery; forming an interconnect member to couple the control module and the power source module, the interconnect member including an electrical conductor that extends through the interconnect member to deliver power from the nonhermetic battery to the components; and including a barrier between the components within the control module and the nonhermetic battery within the power source module that substantially impedes movement of substances from the nonhermetic battery to the components.
PCT/US2004/014804 2003-05-16 2004-05-12 Implantable medical device with a nonhermetic battery WO2004103463A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
DE602004029351T DE602004029351D1 (en) 2003-05-16 2004-05-12 IMPLANTABLE MEDICAL DEVICE WITH A NON-HERMETIC BATTERY
AT04751949T ATE482741T1 (en) 2003-05-16 2004-05-12 IMPLANTABLE MEDICAL DEVICE HAVING A NON-HERMETIC BATTERY
EP04751949A EP1624923B1 (en) 2003-05-16 2004-05-12 Implantable medical device with a nonhermetic battery

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US47126203P 2003-05-16 2003-05-16
US60/471,262 2003-05-16
US10/835,233 2004-04-29
US10/835,233 US7263401B2 (en) 2003-05-16 2004-04-29 Implantable medical device with a nonhermetic battery

Publications (2)

Publication Number Publication Date
WO2004103463A1 true WO2004103463A1 (en) 2004-12-02
WO2004103463B1 WO2004103463B1 (en) 2005-04-07

Family

ID=33479280

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/014804 WO2004103463A1 (en) 2003-05-16 2004-05-12 Implantable medical device with a nonhermetic battery

Country Status (5)

Country Link
US (2) US7263401B2 (en)
EP (1) EP1624923B1 (en)
AT (1) ATE482741T1 (en)
DE (1) DE602004029351D1 (en)
WO (1) WO2004103463A1 (en)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003297723A1 (en) * 2002-12-09 2004-06-30 Medtronic, Inc. Reducing relative intermodule motion in a modular implantable medical device
US7596408B2 (en) * 2002-12-09 2009-09-29 Medtronic, Inc. Implantable medical device with anti-infection agent
US20050004637A1 (en) * 2003-05-16 2005-01-06 Ruchika Singhal Explantation of implantable medical device
US7263401B2 (en) 2003-05-16 2007-08-28 Medtronic, Inc. Implantable medical device with a nonhermetic battery
US7317947B2 (en) * 2003-05-16 2008-01-08 Medtronic, Inc. Headset recharger for cranially implantable medical devices
US7756581B2 (en) * 2004-02-18 2010-07-13 Medtronic, Inc. Implantable temperature sensor
US7596399B2 (en) * 2004-04-29 2009-09-29 Medtronic, Inc Implantation of implantable medical device
US20050245984A1 (en) 2004-04-30 2005-11-03 Medtronic, Inc. Implantable medical device with lubricious material
US7545272B2 (en) 2005-02-08 2009-06-09 Therasense, Inc. RF tag on test strips, test strip vials and boxes
US7684864B2 (en) * 2005-04-28 2010-03-23 Medtronic, Inc. Subcutaneous cardioverter-defibrillator
US9307925B2 (en) 2005-06-16 2016-04-12 Aaken Laboratories Methods and systems for generating electrical property maps of biological structures
US8068892B2 (en) * 2005-06-16 2011-11-29 Aaken Labs Methods and systems for using intracranial electrodes
ITMI20051356A1 (en) * 2005-07-15 2007-01-16 Getters Spa GETTER DEVICE FOR ACTIVE SYSTEMS FOR TRANSDERMIC RELEASE OF DRUGS
US7761165B1 (en) 2005-09-29 2010-07-20 Boston Scientific Neuromodulation Corporation Implantable stimulator with integrated plastic housing/metal contacts and manufacture and use
US8248232B2 (en) * 2006-01-25 2012-08-21 Greatbatch Ltd. Hermetically sealed RFID microelectronic chip connected to a biocompatible RFID antenna
US9084901B2 (en) 2006-04-28 2015-07-21 Medtronic, Inc. Cranial implant
US20070266554A1 (en) * 2006-05-16 2007-11-22 Bruce Gregg C Electrochemical cell with moderate-rate discharging capability and method of production
US8401648B2 (en) * 2006-10-31 2013-03-19 Medtronic, Inc. Housing for implantable medical device
US8437855B2 (en) * 2007-04-09 2013-05-07 Bal Seal Engineering, Inc. Connector assembly for use with medical devices
EP2134418B1 (en) * 2007-04-11 2012-06-20 BAL Seal Engineering Integrated header connector system
US7914351B2 (en) * 2007-04-13 2011-03-29 Bal Seal Engineering Electrical connectors with improved electrical contact performance
WO2009076310A2 (en) * 2007-12-06 2009-06-18 Bal Seal Engineering In-line connector
EP2262442B1 (en) * 2008-04-11 2015-03-25 BAL Seal Engineering Connector cartridge stack for electrical transmission
US8314594B2 (en) * 2008-04-30 2012-11-20 Medtronic, Inc. Capacity fade adjusted charge level or recharge interval of a rechargeable power source of an implantable medical device, system and method
US8751010B2 (en) * 2008-04-30 2014-06-10 Medtronic, Inc. Time to next recharge session feedback while recharging an implantable medical device, system and method therefore
US8193766B2 (en) * 2008-04-30 2012-06-05 Medtronic, Inc. Time remaining to charge an implantable medical device, charger indicator, system and method therefore
US20090281623A1 (en) * 2008-05-12 2009-11-12 Medtronic, Inc. Customization of implantable medical devices
US9293849B2 (en) * 2008-07-30 2016-03-22 Bal Seal Engineering, Inc. Electrical connector using a canted coil multi-metallic wire
US9393432B2 (en) 2008-10-31 2016-07-19 Medtronic, Inc. Non-hermetic direct current interconnect
US8096838B2 (en) * 2009-03-11 2012-01-17 Bal Seal Engineering, Inc. Header assembly for implantable medical devices
US8328587B2 (en) 2009-04-20 2012-12-11 Bal Seal Engineering, Inc. In-line connector stack with testing capability
US20100289198A1 (en) * 2009-04-28 2010-11-18 Pete Balsells Multilayered canted coil springs and associated methods
US8594806B2 (en) 2010-04-30 2013-11-26 Cyberonics, Inc. Recharging and communication lead for an implantable device
US8903473B2 (en) 2010-09-15 2014-12-02 Medtronic, Inc. Radiopaque markers for implantable medical devices
US9343923B2 (en) 2012-08-23 2016-05-17 Cyberonics, Inc. Implantable medical device with backscatter signal based communication
US9935498B2 (en) 2012-09-25 2018-04-03 Cyberonics, Inc. Communication efficiency with an implantable medical device using a circulator and a backscatter signal
US9872997B2 (en) 2013-03-15 2018-01-23 Globus Medical, Inc. Spinal cord stimulator system
US9887574B2 (en) 2013-03-15 2018-02-06 Globus Medical, Inc. Spinal cord stimulator system
US9440076B2 (en) 2013-03-15 2016-09-13 Globus Medical, Inc. Spinal cord stimulator system
US9878170B2 (en) 2013-03-15 2018-01-30 Globus Medical, Inc. Spinal cord stimulator system
US9333366B2 (en) 2013-09-05 2016-05-10 Boston Scientific Neuromodulation Corporation Construction for an implantable medical device having a battery affixed to the case
GB2525023B (en) * 2014-04-10 2017-10-04 Cardiola Ltd Apparatus and method for treating a patient having a heart
EP3218052B1 (en) * 2014-11-12 2023-06-21 Medtronic, Inc. Implantable medical devices with electrically isolated batteries in a separate enclosure
US11058541B2 (en) 2015-09-04 2021-07-13 The Johns Hopkins University Low-profile intercranial device
US20200254249A1 (en) 2015-11-17 2020-08-13 Inspire Medical Systems, Inc. Microstimulation sleep disordered breathing (sdb) therapy device
US10576292B2 (en) * 2015-11-29 2020-03-03 Boston Scientific Neuromodulation Corporation Skull-mounted deep brain stimulator
US10912648B2 (en) 2016-08-30 2021-02-09 Longeviti Neuro Solutions Llc Method for manufacturing a low-profile intercranial device and the low-profile intercranial device manufactured thereby
US20180085573A1 (en) 2016-09-27 2018-03-29 National Guard Health Affairs Skull implanted electrode assembly for brain stimulation
JP7218292B2 (en) * 2017-01-10 2023-02-06 インスパイア・メディカル・システムズ・インコーポレイテッド Power Elements of Implantable Medical Devices
US10904680B2 (en) * 2017-02-23 2021-01-26 Advanced Bionics Ag Battery-based systems and methods for managing sound processor programming for a cochlear implant system
US11589992B2 (en) 2018-01-09 2023-02-28 Longeviti Neuro Solutions Llc Universal low-profile intercranial assembly
WO2019143574A1 (en) * 2018-01-16 2019-07-25 Boston Scientific Neuromodulation Corporation An electrical stimulation system with a case-neutral battery and a control module for such a system
EP3762087B1 (en) 2018-03-09 2023-04-26 Boston Scientific Neuromodulation Corporation Burr hole plugs for electrical stimulation systems
WO2019178145A1 (en) 2018-03-16 2019-09-19 Boston Scientific Neuromodulation Corporation Kits and methods for securing a burr hole plugs for stimulation systems
AU2019355911A1 (en) * 2018-10-02 2021-03-18 Longeviti Neuro Solutions Llc Universal power supply for a functional cranial implant

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3690325A (en) * 1969-11-03 1972-09-12 Devices Ltd Implantable electric device
US5702430A (en) * 1992-08-06 1997-12-30 Electric Boat Corporation Surgically implantable power supply
US5741313A (en) * 1996-09-09 1998-04-21 Pacesetter, Inc. Implantable medical device with a reduced volumetric configuration and improved shock stabilization
US6067474A (en) * 1997-08-01 2000-05-23 Advanced Bionics Corporation Implantable device with improved battery recharging and powering configuration
US6272382B1 (en) * 1998-07-31 2001-08-07 Advanced Bionics Corporation Fully implantable cochlear implant system

Family Cites Families (182)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3310051A (en) * 1963-12-10 1967-03-21 Rudolf R Schulte Surgical reservoir for implantation beneath the skin
DE1589587A1 (en) 1966-03-25 1970-04-30 Chirana Zd Y Zdravotnickej Ech Implantable cardiac stimulator
US3522811A (en) * 1969-02-13 1970-08-04 Medtronic Inc Implantable nerve stimulator and method of use
US3724467A (en) * 1971-04-23 1973-04-03 Avery Labor Inc Electrode implant for the neuro-stimulation of the spinal cord
US3888260A (en) * 1972-06-28 1975-06-10 Univ Johns Hopkins Rechargeable demand inhibited cardiac pacer and tissue stimulator
US3913587A (en) * 1973-12-10 1975-10-21 Dow Corning Implantable extendable member
DE2415385A1 (en) * 1974-03-29 1975-10-02 Siemens Ag PACEMAKER
US4040412A (en) * 1974-08-09 1977-08-09 Sato Takuya R Bioelectrodes
US4010760A (en) * 1975-05-23 1977-03-08 Medtronic, Inc. Coupling assembly for implantable electromedical devices
US4006748A (en) * 1976-01-29 1977-02-08 Pacestter Systems, Inc. Implantable unipolar pacemaker with improved outer electrode plate
US4013081A (en) * 1976-04-19 1977-03-22 Arco Medical Products Company Pediatric cardiac pacer system
US4266552A (en) * 1979-11-13 1981-05-12 Medtronic, Inc. Lead anchoring bobbin
DE3034257C2 (en) * 1980-09-11 1983-07-07 Repa Feinstanzwerk Gmbh, 7071 Alfdorf Pyrotechnic drive device, in particular for a tightening device of a seat belt system
US4328813A (en) * 1980-10-20 1982-05-11 Medtronic, Inc. Brain lead anchoring system
DE3107128C2 (en) * 1981-02-26 1984-07-05 Heinze, Roland, Dipl.-Ing., 8000 München Control circuit for adapting the stimulation frequency of a cardiac pacemaker to the load on a patient
US4399819A (en) 1981-12-21 1983-08-23 Telectronics Pty. Ltd. Heart pacer mechanical construction
US4616655A (en) * 1984-01-20 1986-10-14 Cordis Corporation Implantable pulse generator having a single printed circuit board and a chip carrier
US5214032A (en) * 1985-02-08 1993-05-25 Procyte Corporation GHL-CU pharmaceutical compositions and compounds
US4911178A (en) * 1988-06-02 1990-03-27 Neal Carol A Pacemaker wire dressing
US4969899A (en) 1989-03-08 1990-11-13 Cox-Uphoff International Inflatable implant
DE3918086C1 (en) 1989-06-02 1990-09-27 Hortmann Gmbh, 7449 Neckartenzlingen, De
US4928696A (en) * 1989-07-26 1990-05-29 Mindcenter Corporation Electrode-supporting headset
US5271397A (en) 1989-09-08 1993-12-21 Cochlear Pty. Ltd. Multi-peak speech processor
US5085644A (en) * 1990-04-02 1992-02-04 Pudenz-Schulte Medical Research Corporation Sterilizable medication infusion device with dose recharge restriction
US5218959A (en) 1990-10-03 1993-06-15 Fenster Harold A Body implantable electrical signal generator with redundant lead retainer and surgical procedure
US5116345A (en) * 1990-11-28 1992-05-26 Ohio Medical Instrument Co., Inc. Stereotactically implanting an intracranial device
US5207218A (en) 1991-02-27 1993-05-04 Medtronic, Inc. Implantable pulse generator
JPH04338450A (en) * 1991-05-15 1992-11-25 Sharp Corp Pressure cuff and bag apparatus
US5144946A (en) 1991-08-05 1992-09-08 Siemens Pacesetter, Inc. Combined pacemaker substrate and electrical interconnect and method of assembly
US5220929A (en) * 1991-10-02 1993-06-22 Ventritex, Inc. Bio-compatible boot for implantable medical device
US5314453A (en) * 1991-12-06 1994-05-24 Spinal Cord Society Position sensitive power transfer antenna
US5197332A (en) * 1992-02-19 1993-03-30 Calmed Technology, Inc. Headset hearing tester and hearing aid programmer
US5324312A (en) * 1992-05-06 1994-06-28 Medtronic, Inc. Tool-less threaded connector assembly
US5252090A (en) 1992-09-30 1993-10-12 Telectronics Pacing Systems, Inc. Self-locking implantable stimulating lead connector
US5284161A (en) * 1992-11-12 1994-02-08 Karell Manuel L Snopper-the snoring stopper anti-snoring mouth device
US5314451A (en) * 1993-01-15 1994-05-24 Medtronic, Inc. Replaceable battery for implantable medical device
US5531787A (en) 1993-01-25 1996-07-02 Lesinski; S. George Implantable auditory system with micromachined microsensor and microactuator
US5477855A (en) 1993-07-16 1995-12-26 Alfred E. Mann Foundation For Scientific Research Shield for conductors of an implantable device
USH1465H (en) * 1993-09-08 1995-07-04 Medtronic, Inc. Implantable lead infection barrier
US5411537A (en) * 1993-10-29 1995-05-02 Intermedics, Inc. Rechargeable biomedical battery powered devices with recharging and control system therefor
US5573551A (en) 1993-11-01 1996-11-12 Intermedics, Inc. Implantable medical device with detachable battery or electronic circuit
US5411538A (en) * 1993-11-01 1995-05-02 Intermedics, Inc. Implantable medical device with detachable battery or electronic circuit
US5431695A (en) 1993-11-23 1995-07-11 Medtronic, Inc. Pacemaker
US5489225A (en) * 1993-12-16 1996-02-06 Ventritex, Inc. Electrical terminal with a collet grip for a defibrillator
US5800535A (en) * 1994-02-09 1998-09-01 The University Of Iowa Research Foundation Wireless prosthetic electrode for the brain
US5843093A (en) * 1994-02-09 1998-12-01 University Of Iowa Research Foundation Stereotactic electrode assembly
US5697975A (en) 1994-02-09 1997-12-16 The University Of Iowa Research Foundation Human cerebral cortex neural prosthetic for tinnitus
US5419977A (en) * 1994-03-09 1995-05-30 Medtronic, Inc. Electrochemical device having operatively combined capacitor
US5645586A (en) * 1994-07-08 1997-07-08 Ventritex, Inc. Conforming implantable defibrillator
US5571148A (en) 1994-08-10 1996-11-05 Loeb; Gerald E. Implantable multichannel stimulator
US5458997A (en) 1994-08-19 1995-10-17 Medtronic, Inc. Rebalancing of lithium/silver vandium oxide (Li/SVO) cells for improved performance
CA2131777A1 (en) * 1994-09-09 1996-03-10 Allen Shkuratoff Sealed electrical device with unitary fill port and terminal construction
US5480416A (en) * 1994-09-22 1996-01-02 Intermedics, Inc. Cardiac pacemaker with universal coating
AU708529B2 (en) 1994-11-10 1999-08-05 University Of Kentucky Research Foundation, The Implantable refillable controlled release device to deliver drugs directly to an internal portion of the body
US5562715A (en) 1994-12-01 1996-10-08 Czura; John J. Cardiac pulse generator
US5678559A (en) * 1995-01-23 1997-10-21 Drakulic; Budimir S. Eeg system
US5554194A (en) * 1995-06-07 1996-09-10 United States Surgical Corporation Modular surgical implant
US5638832A (en) * 1995-06-07 1997-06-17 Interval Research Corporation Programmable subcutaneous visible implant
US6944501B1 (en) 2000-04-05 2005-09-13 Neurospace, Inc. Neurostimulator involving stimulation strategies and process for using it
US20020169485A1 (en) 1995-10-16 2002-11-14 Neuropace, Inc. Differential neurostimulation therapy driven by physiological context
US6480743B1 (en) 2000-04-05 2002-11-12 Neuropace, Inc. System and method for adaptive brain stimulation
US6558686B1 (en) 1995-11-08 2003-05-06 Baylor College Of Medicine Method of coating medical devices with a combination of antiseptics and antiseptic coating therefor
US5792067A (en) * 1995-11-21 1998-08-11 Karell; Manuel L. Apparatus and method for mitigating sleep and other disorders through electromuscular stimulation
WO1997029802A2 (en) 1996-02-20 1997-08-21 Advanced Bionics Corporation Improved implantable microstimulator and systems employing the same
US5674260A (en) 1996-02-23 1997-10-07 Pacesetter, Inc. Apparatus and method for mounting an activity sensor or other component within a pacemaker using a contoured hybrid lid
SE9601154D0 (en) * 1996-03-26 1996-03-26 Pacesetter Ab Active implant
US5895414A (en) * 1996-04-19 1999-04-20 Sanchez-Zambrano; Sergio Pacemaker housing
DE19622669A1 (en) * 1996-06-05 1997-12-11 Implex Gmbh Implantable unit
US5773961A (en) * 1996-06-06 1998-06-30 Heartstream, Inc. Dynamic load controller for a battery
US5814095A (en) * 1996-09-18 1998-09-29 Implex Gmbh Spezialhorgerate Implantable microphone and implantable hearing aids utilizing same
US5830137A (en) 1996-11-18 1998-11-03 University Of South Florida Green light pulse oximeter
US5876424A (en) * 1997-01-23 1999-03-02 Cardiac Pacemakers, Inc. Ultra-thin hermetic enclosure for implantable medical devices
US5749911A (en) * 1997-01-24 1998-05-12 Cardiac Pacemakers, Inc. Implantable tissue stimulator incorporating deposited multilayer capacitor
US5991664A (en) 1997-03-09 1999-11-23 Cochlear Limited Compact inductive arrangement for medical implant data and power transfer
US5776169A (en) * 1997-04-28 1998-07-07 Sulzer Intermedics Inc. Implantable cardiac stimulator for minimally invasive implantation
FR2765486B1 (en) 1997-07-03 1999-10-01 Ela Medical Sa SYSTEM FOR THE MECHANICAL IMMOBILIZATION OF A PROBE CONNECTOR IN AN ACTIVE IMPLANTABLE MEDICAL DEVICE GENERATOR CONNECTOR, IN PARTICULAR FOR A HEART STIMULATOR, DEFIBRILLATOR AND / OR CARDIOVERTER
US5871514A (en) * 1997-08-01 1999-02-16 Medtronic, Inc. Attachment apparatus for an implantable medical device employing ultrasonic energy
US6205358B1 (en) * 1997-08-01 2001-03-20 Medtronic, Inc. Method of making ultrasonically welded, staked of swaged components in an implantable medical device
US6248080B1 (en) * 1997-09-03 2001-06-19 Medtronic, Inc. Intracranial monitoring and therapy delivery control device, system and method
US6516808B2 (en) * 1997-09-12 2003-02-11 Alfred E. Mann Foundation For Scientific Research Hermetic feedthrough for an implantable device
WO1999017585A1 (en) * 1997-09-29 1999-04-08 Cochlear Limited Public alarm apparatus and method for cochlear implants
US5843150A (en) 1997-10-08 1998-12-01 Medtronic, Inc. System and method for providing electrical and/or fluid treatment within a patient's brain
US5941906A (en) * 1997-10-15 1999-08-24 Medtronic, Inc. Implantable, modular tissue stimulator
US6230049B1 (en) * 1999-08-13 2001-05-08 Neuro Pace, Inc. Integrated system for EEG monitoring and electrical stimulation with a multiplicity of electrodes
US6016449A (en) * 1997-10-27 2000-01-18 Neuropace, Inc. System for treatment of neurological disorders
US6647296B2 (en) 1997-10-27 2003-11-11 Neuropace, Inc. Implantable apparatus for treating neurological disorders
US6354299B1 (en) * 1997-10-27 2002-03-12 Neuropace, Inc. Implantable device for patient communication
US6597954B1 (en) * 1997-10-27 2003-07-22 Neuropace, Inc. System and method for controlling epileptic seizures with spatially separated detection and stimulation electrodes
US6427086B1 (en) * 1997-10-27 2002-07-30 Neuropace, Inc. Means and method for the intracranial placement of a neurostimulator
ATE280555T1 (en) * 1998-01-12 2004-11-15 Ronald P Lesser METHOD FOR TREATING BRAIN DISEASE USING CONTROLLED HEAT SUPPLY
US5958088A (en) 1998-03-04 1999-09-28 Duracell, Inc. Prismatic cell construction
US6016593A (en) * 1998-04-10 2000-01-25 Kyrstein Investments Ltd. Electric drive system for planer mill infeed and outfeed rolls
US6266556B1 (en) * 1998-04-27 2001-07-24 Beth Israel Deaconess Medical Center, Inc. Method and apparatus for recording an electroencephalogram during transcranial magnetic stimulation
US6044304A (en) * 1998-04-29 2000-03-28 Medtronic, Inc. Burr ring with integral lead/catheter fixation device
US6006124A (en) 1998-05-01 1999-12-21 Neuropace, Inc. Means and method for the placement of brain electrodes
DE19827898C1 (en) 1998-06-23 1999-11-11 Hans Leysieffer Electrical energy supply for an implant, eg. a hearing aid
DE19829637C2 (en) * 1998-07-02 2000-10-19 Implex Hear Tech Ag Medical implant
US6091979A (en) * 1998-07-07 2000-07-18 Children's Medical Center Corporation Subdural electrode arrays for monitoring cortical electrical activity
US6308101B1 (en) 1998-07-31 2001-10-23 Advanced Bionics Corporation Fully implantable cochlear implant system
US6366813B1 (en) * 1998-08-05 2002-04-02 Dilorenzo Daniel J. Apparatus and method for closed-loop intracranical stimulation for optimal control of neurological disease
DE19837913C2 (en) 1998-08-20 2000-09-28 Implex Hear Tech Ag Implantable device with a charging current feed arrangement having a receiving coil
DE19837912C1 (en) 1998-08-20 1999-10-28 Implex Hear Tech Ag Energy supply module for implanted device e.g. hearing aid or tinnitus masking device, heart pacemaker or drug dispenser
US6299980B1 (en) * 1998-09-29 2001-10-09 Medtronic Ave, Inc. One step lubricious coating
US7062330B1 (en) 1998-10-26 2006-06-13 Boveja Birinder R Electrical stimulation adjunct (Add-ON) therapy for urinary incontinence and urological disorders using implanted lead stimulus-receiver and an external pulse generator
US6259266B1 (en) * 1998-10-27 2001-07-10 Apack Technologies Inc. Testing device and method for known good chip
US6436422B1 (en) 1998-11-23 2002-08-20 Agion Technologies L.L.C. Antibiotic hydrophilic polymer coating
WO2000040295A1 (en) * 1999-01-06 2000-07-13 Ball Semiconductor, Inc. Implantable neuro-stimulator
US6168580B1 (en) * 1999-03-26 2001-01-02 Iontophoretics Corporation Antimicrobial device and methods for long-term catheters
US6324428B1 (en) 1999-03-30 2001-11-27 Pacesetter, Inc. Implantable medical device having an improved electronic assembly for increasing packaging density and enhancing component protection
US6259951B1 (en) 1999-05-14 2001-07-10 Advanced Bionics Corporation Implantable cochlear stimulator system incorporating combination electrode/transducer
US6516227B1 (en) * 1999-07-27 2003-02-04 Advanced Bionics Corporation Rechargeable spinal cord stimulator system
US6560486B1 (en) * 1999-10-12 2003-05-06 Ivan Osorio Bi-directional cerebral interface system
US6882881B1 (en) 1999-10-19 2005-04-19 The Johns Hopkins University Techniques using heat flow management, stimulation, and signal analysis to treat medical disorders
US6358281B1 (en) * 1999-11-29 2002-03-19 Epic Biosonics Inc. Totally implantable cochlear prosthesis
US6356792B1 (en) * 2000-01-20 2002-03-12 Electro Core Technologies, Llc Skull mounted electrode lead securing assembly
US6324433B1 (en) 2000-01-20 2001-11-27 Electrocare Technologies, Llc Electrode-lead coupling skull mounted port assembly
US6920359B2 (en) 2000-02-15 2005-07-19 Advanced Bionics Corporation Deep brain stimulation system for the treatment of Parkinson's Disease or other disorders
US6627337B2 (en) 2000-02-16 2003-09-30 Wilson Greatbatch Ltd. Conversion of low rate energy into high rate energy by parallel discharging
AU5095601A (en) 2000-03-24 2001-10-08 Cymbet Corp Thin-film battery having ultra-thin electrolyte and associated method
DE10015421C2 (en) * 2000-03-28 2002-07-04 Implex Ag Hearing Technology I Partially or fully implantable hearing system
US6466822B1 (en) 2000-04-05 2002-10-15 Neuropace, Inc. Multimodal neurostimulator and process of using it
US6478776B1 (en) * 2000-04-05 2002-11-12 Biocardia, Inc. Implant delivery catheter system and methods for its use
DE10018361C2 (en) * 2000-04-13 2002-10-10 Cochlear Ltd At least partially implantable cochlear implant system for the rehabilitation of a hearing disorder
DE10018360C2 (en) * 2000-04-13 2002-10-10 Cochlear Ltd At least partially implantable system for the rehabilitation of a hearing impairment
US6490486B1 (en) 2000-04-27 2002-12-03 Pacesetter, Inc. Implantable cardiac stimulation device and method that monitors displacement of an implanted lead
US6517476B1 (en) * 2000-05-30 2003-02-11 Otologics Llc Connector for implantable hearing aid
US6505077B1 (en) * 2000-06-19 2003-01-07 Medtronic, Inc. Implantable medical device with external recharging coil electrical connection
US6782292B2 (en) * 2000-06-20 2004-08-24 Advanced Bionics Corporation System and method for treatment of mood and/or anxiety disorders by electrical brain stimulation and/or drug infusion
EP2326107B1 (en) * 2000-06-30 2016-08-10 Cochlear Limited Cochlear implant
US20030125786A1 (en) * 2000-07-13 2003-07-03 Gliner Bradford Evan Methods and apparatus for effectuating a lasting change in a neural-function of a patient
US7756584B2 (en) * 2000-07-13 2010-07-13 Advanced Neuromodulation Systems, Inc. Methods and apparatus for effectuating a lasting change in a neural-function of a patient
US7010351B2 (en) * 2000-07-13 2006-03-07 Northstar Neuroscience, Inc. Methods and apparatus for effectuating a lasting change in a neural-function of a patient
DE10041727C2 (en) * 2000-08-25 2003-04-10 Cochlear Ltd Implantable hermetically sealed housing for an implantable medical device
DE10041728A1 (en) * 2000-08-25 2002-03-21 Implex Hear Tech Ag Implantable medicinal device with hermetically sealed housing has storage device accommodated directly within hermetically sealed housing without housing of its own
DE10041726C1 (en) * 2000-08-25 2002-05-23 Implex Ag Hearing Technology I Implantable hearing system with means for measuring the coupling quality
GB2370509A (en) * 2000-08-29 2002-07-03 Don Edward Casey Subcutaneously implanted photovoltaic power supply
US7039465B2 (en) * 2000-09-18 2006-05-02 Cameron Health, Inc. Ceramics and/or other material insulated shell for active and non-active S-ICD can
US6788974B2 (en) 2000-09-18 2004-09-07 Cameron Health, Inc. Radian curve shaped implantable cardioverter-defibrillator canister
US7120495B2 (en) * 2000-09-18 2006-10-10 Cameron Health, Inc. Flexible subcutaneous implantable cardioverter-defibrillator
US7194309B2 (en) 2000-09-18 2007-03-20 Cameron Health, Inc. Packaging technology for non-transvenous cardioverter/defibrillator devices
US6405079B1 (en) * 2000-09-22 2002-06-11 Mehdi M. Ansarinia Stimulation method for the dural venous sinuses and adjacent dura for treatment of medical conditions
US6498951B1 (en) * 2000-10-13 2002-12-24 Medtronic, Inc. Implantable medical device employing integral housing for a formable flat battery
US6567703B1 (en) * 2000-11-08 2003-05-20 Medtronic, Inc. Implantable medical device incorporating miniaturized circuit module
ATE369151T1 (en) * 2000-11-09 2007-08-15 Astrazeneca Ab ORAL PHARMACEUTICAL COMPOSITION CONTAINING A BLOCK COPOLYMER
US6618623B1 (en) * 2000-11-28 2003-09-09 Neuropace, Inc. Ferrule for cranial implant
US6726678B1 (en) * 2001-02-22 2004-04-27 Isurgical, Llc Implantable reservoir and system for delivery of a therapeutic agent
US7299096B2 (en) 2001-03-08 2007-11-20 Northstar Neuroscience, Inc. System and method for treating Parkinson's Disease and other movement disorders
US6622046B2 (en) 2001-05-07 2003-09-16 Medtronic, Inc. Subcutaneous sensing feedthrough/electrode assembly
US6671544B2 (en) 2001-06-28 2003-12-30 Medtronic, Inc. Low impedance implantable extension for a neurological electrical stimulator
US6810285B2 (en) * 2001-06-28 2004-10-26 Neuropace, Inc. Seizure sensing and detection using an implantable device
ATE460753T1 (en) * 2001-07-19 2010-03-15 Greatbatch Ltd CURVED HOUSING FOR AN IMPLANTABLE MEDICAL DEVICE
US6977124B2 (en) 2001-07-19 2005-12-20 Wilson Greatbatch Technologies, Inc. Contoured casing for an electrochemical cell
US6456256B1 (en) 2001-08-03 2002-09-24 Cardiac Pacemakers, Inc. Circumferential antenna for an implantable medical device
US6626680B2 (en) * 2001-08-24 2003-09-30 Wilson Greatbatch Ltd. Wire bonding surface
US7070881B2 (en) 2001-10-18 2006-07-04 Quallion Llc Electrical battery assembly and method of manufacture
US6788976B2 (en) * 2001-11-02 2004-09-07 Lockheed Martin Corporation Movement timing simulator
US6894456B2 (en) * 2001-11-07 2005-05-17 Quallion Llc Implantable medical power module
US20030109903A1 (en) * 2001-12-12 2003-06-12 Epic Biosonics Inc. Low profile subcutaneous enclosure
US6963780B2 (en) 2002-01-31 2005-11-08 Medtronic, Inc. Implantable medical device including a surface-mount terminal array
US7110819B1 (en) 2002-03-05 2006-09-19 Pacesetter, Inc. Implantable medical device having a protected connection header
US6968234B2 (en) 2002-04-25 2005-11-22 Medtronic, Inc. Implantable medical device having biologically active polymeric casing
AU2002950755A0 (en) 2002-08-09 2002-09-12 Cochlear Limited Fixation system for a cochlear implant
US6994933B1 (en) * 2002-09-16 2006-02-07 Oak Ridge Micro-Energy, Inc. Long life thin film battery and method therefor
US20050075679A1 (en) 2002-09-30 2005-04-07 Gliner Bradford E. Methods and apparatuses for treating neurological disorders by electrically stimulating cells implanted in the nervous system
US20040064163A1 (en) * 2002-09-30 2004-04-01 Aamodt Paul B. Contoured battery for implantable medical devices and method of manufacture
US6931284B2 (en) * 2002-10-25 2005-08-16 Medtronic, Inc. Implantable medical device with air core antenna assembly
US7302298B2 (en) * 2002-11-27 2007-11-27 Northstar Neuroscience, Inc Methods and systems employing intracranial electrodes for neurostimulation and/or electroencephalography
AU2003297761A1 (en) 2002-12-09 2004-06-30 Northstar Neuroscience, Inc. Methods for treating neurological language disorders
US7596408B2 (en) 2002-12-09 2009-09-29 Medtronic, Inc. Implantable medical device with anti-infection agent
AU2003297723A1 (en) 2002-12-09 2004-06-30 Medtronic, Inc. Reducing relative intermodule motion in a modular implantable medical device
US20040186528A1 (en) 2003-03-20 2004-09-23 Medtronic, Inc. Subcutaneous implantable medical devices with anti-microbial agents for chronic release
US20050004637A1 (en) 2003-05-16 2005-01-06 Ruchika Singhal Explantation of implantable medical device
US7263401B2 (en) 2003-05-16 2007-08-28 Medtronic, Inc. Implantable medical device with a nonhermetic battery
US20050003268A1 (en) 2003-05-16 2005-01-06 Scott Erik R. Battery housing configuration
US7317947B2 (en) 2003-05-16 2008-01-08 Medtronic, Inc. Headset recharger for cranially implantable medical devices
US7454251B2 (en) 2003-05-29 2008-11-18 The Cleveland Clinic Foundation Excess lead retaining and management devices and methods of using same
JP2007501067A (en) 2003-08-01 2007-01-25 ノーススター ニューロサイエンス インコーポレイテッド Apparatus and method for applying neural stimulation to patient
US7107097B2 (en) 2004-01-14 2006-09-12 Northstar Neuroscience, Inc. Articulated neural electrode assembly
US7596399B2 (en) 2004-04-29 2009-09-29 Medtronic, Inc Implantation of implantable medical device
US20050245984A1 (en) 2004-04-30 2005-11-03 Medtronic, Inc. Implantable medical device with lubricious material
US7783359B2 (en) 2005-01-05 2010-08-24 Boston Scientific Neuromodulation Corporation Devices and methods using an implantable pulse generator for brain stimulation
US9084901B2 (en) 2006-04-28 2015-07-21 Medtronic, Inc. Cranial implant

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3690325A (en) * 1969-11-03 1972-09-12 Devices Ltd Implantable electric device
US5702430A (en) * 1992-08-06 1997-12-30 Electric Boat Corporation Surgically implantable power supply
US5741313A (en) * 1996-09-09 1998-04-21 Pacesetter, Inc. Implantable medical device with a reduced volumetric configuration and improved shock stabilization
US6067474A (en) * 1997-08-01 2000-05-23 Advanced Bionics Corporation Implantable device with improved battery recharging and powering configuration
US6272382B1 (en) * 1998-07-31 2001-08-07 Advanced Bionics Corporation Fully implantable cochlear implant system

Also Published As

Publication number Publication date
US20050004618A1 (en) 2005-01-06
DE602004029351D1 (en) 2010-11-11
US7881796B2 (en) 2011-02-01
US20080021511A1 (en) 2008-01-24
EP1624923A1 (en) 2006-02-15
WO2004103463B1 (en) 2005-04-07
EP1624923B1 (en) 2010-09-29
ATE482741T1 (en) 2010-10-15
US7263401B2 (en) 2007-08-28

Similar Documents

Publication Publication Date Title
EP1624923B1 (en) Implantable medical device with a nonhermetic battery
US7212864B2 (en) Modular implantable medical device
US9162072B2 (en) Implantable medical device with lubricious material
US9393432B2 (en) Non-hermetic direct current interconnect
EP2038001B1 (en) Implantable medical devices having a liquid crystal polymer housing
US20050003268A1 (en) Battery housing configuration
US20130196214A1 (en) Medical device battery enclosure
US11291841B2 (en) Implantable medical device structures including recharge and/or telemetry coil

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
B Later publication of amended claims

Effective date: 20041213

WWE Wipo information: entry into national phase

Ref document number: 2004751949

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004751949

Country of ref document: EP